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Abstract 
Aberrant DNA methylation of CpG sites has been linked to the aetiology and pathogenesis of 
various malignancies including acute myeloid leukemia (AML). Decitabine is a drug which 
has been shown to reduce methylation levels, and is being increasingly explored as an agent 
for treating cancer. However, the determinants of demethylation caused by decitabine are not 
completely understood. 
The purposes of this study were to investigate the determinants of the demethylation observed 
following treatment of AML samples with decitabine, and to explore whether these 
determinants could explain the variation in demethylation across two AML cell lines and 
eight primary cultures from AML patients.  
The results showed considerable variation in the level of demethylation between samples. 
Within samples, CpG demethylation was found to vary according to CpG location, CpG 
density, proximity to a CpG island and pre-treatment methylation levels. Multivariate 
regression analysis showed that the principal determinant of demethylation at an individual 
CpG site was the pre-treatment methylation level. However, the analysis also showed that the 
determinants identified were in themselves insufficient to explain all of the variation in 
demethylation observed across study samples. 
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1.  Introduction 
This project examined the effect of  a global demethylating agent, decitabine (DAC), on the 
methylation profiles of acute myeloid leukemia cells taken from eight paediatric patients and 
two cell lines. 
1.1 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a cancer of blood cells which typically, but not 
exclusively, affects older people and is caused by the proliferation of  abnormal white blood 
cells which interfere with the production and function of normal blood cells.  
AML has a heterogeneous genetic basis, and certain known chromosomal abnormalities are 
used to classify patients into favourable, intermediate and unfavourable prognostic groups
1
. 
Furthermore there are a small number of single gene mutations which have been discovered to 
be markers of good (NPM1) and bad (FLT3) prognosis
2
. It is also believed that epigenetic 
modifications, in particular abnormal levels of methylation, to the underlying DNA have a 
causal implication in AML initiation
3
. 
1.2 DNA methylation 
Methylation is a chemical process which modifies DNA in such a way that the change can be 
inherited (via cell division) without changing the underlying DNA sequence. It typically 
affects the cytosine element of a cytosine/guanine di-nucleotide (referred to as a "CpG site"), 
whereby the cytosine is chemically tagged by a methyl group. 
Methylation has a key role in the normal regulation of gene activity - typically methylation of 
a gene's promoter will result in repression of that gene, whereas methylation of CpG sites 
within the gene body itself can be associated with gene activation
4
.  
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Maintenance of methylation levels is controlled by a family of enzymes known as DNA 
methyltransferases (DNMTs).  Once a piece of DNA has been methylated, it can be bound by 
methyl-binding proteins, which in turn recruit enzymes that modify the structure of the 
surrounding chromatin in such a way that results in repressed gene expression
5
. 
1.3 Cancer and methylation 
It is unsurprising that abnormal levels of DNA methylation have been linked to a number of 
cancers, including AML
6
. This typically takes the form of abnormally high (hyper-) 
methylation of the promoters of tumour suppressor genes, thereby causing the affected genes 
to become inactive, and thus facilitating loss of control over cell proliferation, potentially 
leading to cancer. CDKN2B and CEBPA are two examples of tumour suppressor genes which 
are silenced in AML as a result of abnormal methylation
7
. 
1.4 Decitabine (DAC) 
As mentioned above, methylation levels across the genome are controlled by DNMTs. Hence, 
inhibiting the activity of DNMTs in cancerous cells is a potential means of reversing 
abnormally high methylation and thereby restoring the functionality of affected tumour 
suppressor genes. This is how DAC works via its effect on one of the DNMTs known as 
DNMT1
8
.  
The precise way in which DAC achieves this is not fully understood, but in broad terms it 
manages to incorporate itself into DNA and then bond with and trap DNMT1, thus inhibiting 
its activity
9
. This leads to what is known as "passive" demethylation whereby the high level of 
hyper-methylation becomes diluted following cell replication and division. DAC has been 
approved for the treatment of myelodysplastic syndrome, which is a preleukemic bone 
marrow disorder. 
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1.5 Genome-wide DNA methylation profiling 
Over recent years there have been considerable technological developments enabling more 
efficient and accurate DNA methylation profiling at individual base-pair resolution on a 
genome-wide scale
10
. In particular, microarrays which use DNA hybridisation techniques 
have been adapted for this purpose. Furthermore, next generation sequencing technologies are 
also now beginning to be adopted. 
Before the profiling by microarray or other technology takes place, a special preparatory step 
is generally required to be applied to the DNA because methylated and  unmethylated 
cytosines are indistinguishable by these technologies
10
. The three key techniques used for this 
are: 
1. digestion with restriction enzymes which are sensitive to methylation status;  
2. affinity enrichment using antibodies which are specific for methylated cytosines; and 
3. bisulphite conversion whereby DNA is treated with sodium bisulphite which causes 
unmethylated cytosines to be converted to uracil whilst methylated cytosines are 
unaltered.  
This project was based on the results of DNA methylation profiling performed using the 
Infinium HumanMethylation450 BeadChip produced by Illumina Inc. This is an array-based 
technology which analyses DNA samples which have been bisulphite converted. 
1.6 Aims of project 
Whilst DAC is known to be a demethylating agent, the extent to which it demethylates 
individual CpG sites is not uniform across the whole human genome. Hence, the key aims of 
this project were to investigate, on a genome-wide scale, the determinants of demethylation 
4 
 
observed following treatment of AML samples with DAC, and to explore whether these 
determinants could explain the variation in demethylation across samples. For this purpose, 
DNA samples had previously been taken from eight paediatric patients suffering from acute 
myeloid leukemia and also two AML cell lines. The methylation profiles of these samples had 
been measured both before and after treatment with DAC using the Illumina array, and these 
values were compared across individual CpG sites.  
The most directly comparable item of previous research in this area
11
 indicated that the level 
of demethylation of individual CpG sites following the administration of  DAC to AML cell 
lines appears to be highly dependent on the initial (pre-treatment) level of methylation - i.e. 
demethylation is greater for CpG sites with a higher pre-treatment level of demethylation, and 
vice-versa. The same research also showed that CpG sites in so-called CpG islands
12
 
experienced lower demethylation than those outside such islands.  However, this research was 
based on an older version of the Infinium technology which has since been upgraded 
considerably. This project uses the new technology (details in section 2), which allows much 
greater refinement of the analysis. Furthermore this project also uses patient samples as well 
as cell lines, and hence is based on data which has been extracted from sources which are 
closer to actual clinical reality. 
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2. Data and methods 
Details of the data and methods used for this project are set out in the sections below. The 
experimental work described in sections 2.1 to 2.3 was performed by other people. The 
analysis of the resultant data carried out for this project is described in sections 2.4 and 2.5. 
2.1 Sample data 
The analysis was based on samples taken from eight, untreated paediatric patients with AML 
and from two AML cell lines (HL60 and KGIA). These samples were processed for 
methylation analyses between Autumn and October 2011 within the School of Cancer 
Sciences at the University of Birmingham.  Patient samples are referred to as APAL, CBUN, 
DONCO, GALWIL, NALE, RILNIA, ROSBOS and ZPEA.  Primary cultures were 
established from AML mononuclear cells isolated from bone marrow cells of the eight 
patients. There were no technical replicates for any of the samples. 
In order to assess the impact of treatment on methylation status, each sample was treated in 
vitro with 0.05µM of DAC. Genome-wide methylation analysis was performed on each of 
these samples both before treatment and five days after treatment. The combination of 
treatment with 0.05µM of DAC and subsequent measurement after 5 days was found to result 
in the greatest decrease in methylation levels by using pyrosequencing on four sample genes. 
This analysis forms part of a larger project looking into the impact of treatment with DAC on 
AML cell viability and linking the results to associated changes in gene expression. Initial 
results of viability assays indicate that samples from seven of the eight patients experienced 
reduced viability following treatment with DAC, with APAL being the one exception. 
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2.2 Methylation profiling 
The genome-wide methylation analysis was performed using the Infinium 
HumanMethylation450 BeadChip produced by Illumina Inc. This is described in detail in the 
paper by Bibikova et al
13
. Briefly, the Infinium array allows high resolution interrogation of 
over 480,000 individual CpG sites for up to 12 samples simultaneously. It is based on a 
combination of Infinium I and Infinium II techniques, which both analyse bisulphite-
converted DNA.  
The Infinium I technology works by having two "beads" for each targetted CpG site which are 
used to hybridise with the sample DNA. For any particular CpG site, one of the beads is 
designed to hybridise with an unmethylated cytosine, whilst the other will hybridise with a 
methylated cytosine. The methylation proportion for the CpG site is the ratio of the number of 
hybridisations with the latter to the total number of hybridisations, with each hybridisation 
being recorded by detection of a (green) fluorescently labelled nucleotide.  
The Infinium II technology uses only one bead for each CpG site. The methylation status is 
determined by single-base extension, whereby a red fluorescently labelled adenine will 
hybridise to an unmethylated (thymine) locus and a green fluorescently labelled guanine will 
hybridise to a methylated (cytosine) locus. The methylation proportion for a CpG site is then 
determined as the ratio of the amount of green fluorescence detected divided by the total of 
red and green fluorescence detected. 
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Figure 1 below is a schematic of the analysis process taken from the Bibikova paper. 
 
Figure 1 - schematic of (A) Infinium I and (B) Infinium II technology 
 
To facilitate downstream analysis of the results, each CpG site is associated with two separate 
labels. The first relates to its location relative to the nearest gene (hereafter referred to as 
"gene location"), and the second its location relative to the nearest CpG island ("CpG island 
region"). Tables 1 and 2 show descriptions of the classifications used in the different labels. 
Gene location Description 
  
Body Region between 3'UTR and 1st exon 
1st exon 1st exon 
3'UTR Untranslated region at the 3' end 
5'UTR Untranslated region at the 5' end 
TSS1500 Region between 200 and 1,500 bases upstream of the transcriptional start site 
TSS200 Region from the transcriptional start site to 200 bases upstream of this 
Sites which do not fall into any of the above categories are unlabelled. For the purposes of this 
project, these have been called "intergenic". 
Table 1 - list of gene location labels used to categorise individual CpG sites 
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CpG island 
region 
Description 
  
Island12 >=500bp region with more than 50% GC composition and CpG 
observed/expected ratio of at least 60% 
North shore14 2kb region upstream of an island 
South shore 2kb region downstream of an island 
North shelf 2kb region upstream of a north shore 
South shelf 2kb region downstream of a south shore 
Sites which do not fall into any of the above categories are unlabelled. For the purposes of this 
project, these have been called "ocean". 
Table 2 - list of CpG island regions used to categorise individual CpG sites 
A schematic representation of these labels, taken from the Bibikova paper, is shown below in 
figure 2: 
 
Figure 2 - schematic of (A) gene locations and (B) CpG island regions 
 
2.3 Raw data processing 
 In order to calculate the methylation status for each CpG site for each sample (both before 
and after treatment with DAC), the raw data produced by the Infinium array were processed 
using the Genome Studio (version 1.8) software produced by Illumina. No normalisation or 
background control adjustment was applied.  
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In order to check the accuracy of the output, pyrosequencing was also performed, for all eight 
patient samples, on four selected genes. The pyrosequencing analysis  confirmed the Illumina 
array results for all samples and candidate genes within a reasonable margin of error, which 
was estimated to be of the order of 5%.  
The key output provided by the Illumina array is the so-called beta-value for each CpG site. 
For any particular CpG site, this represents the average level of methylation detected across 
all the probes for that site, and ranges from 0% (totally unmethylated) to 100% (totally 
methylated). The beta value data were the starting point for this project. 
2.4 Initial filtering of raw beta values 
Whenever the Infinium array is used, it is possible that it may not function properly for some 
of the CpG sites and, therefore, may not adequately measure their methylation statuses. The 
extent of any malfunctioning  can be investigated for each CpG site by looking at the so-
called "detection p-values" output by the Genome Studio software. The detection-p-value for 
each CpG site is calculated by comparing each of the measured methylated probe and 
demethylated probe intensities with the intensity distribution of negative control probes. For 
any given CpG site, a high p-value indicates that there is a potential problem with the probes 
for that site. 
In order to filter out those sites for which the beta values calculated by Genome Studio were 
deemed to be too unreliable for the purposes of this study, software called IMA (Illumina 
Methylation Analyzer)
15
, developed for the programming language R, was used. Any sites for 
which at least 75% of samples had a detection p-value greater than 5% were filtered out using 
this software. All other sites which passed this test were used in the next stage of analysis. 
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2.5 Analysis of filtered beta values 
The key part of the analysis was to investigate the factors which appear to impact on the 
change in methylation level caused by treatment with DAC.  
The change in methylation level for an individual CpG site can be calculated in two different 
ways. Firstly, the arithmetical difference between average beta values before and after 
treatment could be used - for example, if the pre-treatment average beta value is 80% and the 
post-treatment value is 60%, then this would represent a reduction of 20%. This type of 
change is hereafter referred to as the "absolute" change. An alternative way of calculating the 
change is to look at the proportionate change - using the same example, the proportionate 
change (reduction in this case) would be 25% (because 20% is 25% of 80%). 
Previous literature (e.g. the Hagemann paper
11
) has tended to analyse absolute rather than 
proportionate changes. A key disadvantage of using proportionate changes is that, when 
applied to small initial values, large proportionate changes still result in small absolute 
changes which are potentially within the margin of error of the measurement accuracy of the 
Infinium array. Hence analysis based on proportionate changes could be subject to distortion 
caused by measurement inaccuracy. 
Based on an analysis of completely separate data which contained two sets of two technical 
replicates, this study has found that 99.5% of all pairs of replicate beta value measurements 
using the Illumina array had an absolute difference of no more than 10%. However, if 
proportionate differences are considered, then the maximum difference covering 99.5% of all 
pairs is much higher at 67%. At the lower confidence level of 95%, the upper bounds are 5% 
(absolute differences) and 30% (proportionate). 
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Given the potential for introducing distortions if proportionate changes are used, this study 
has concentrated mainly on absolute changes, and these are what are used in the text unless 
otherwise stated. However, proportionate changes do also need to be considered, as they may 
result in different conclusions being reached. Hence, results using proportionate changes are 
also included in various parts of section 3. 
Four key factors were identifed as being potentially associated with the changes in beta  
value. These are: 
 starting (pre-treatment) beta value 
 gene location 
 CpG island region 
 CpG density 
The first three of these variables are all directly available from the Genome Studio output. 
The fourth was calculated using a piece of code written in R (using the BSgenome package 
for genome information).  For this purpose, CpG density was calculated for each CpG site 
across a 500bp region centred on the site. The total number of CG dinucleotides in the 500bp 
region was used as the measure of CpG density.  
The associations of the four factors identified above with the change in beta value were then 
analysed using a mixture of programs written in R and Microsoft Excel. In particular, both 
linear and logistic regression analyses were performed in R (using the lm and glm functions 
respectively), and kernel density plots were created in R using the density function. For the 
logistic regression analysis, Nagelkerke's R
2
 measure of association
16
 was calculated using the 
fmsb package. 
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3. Results 
The results of the analysis are set out in the paragraphs below. 
Orientation of analysis 
As previously stated, the aim of this study is to attempt to explain the variation in the level of 
demethylation of CpG sites in AML cell lines and patient samples following treatment with 
decitabine. The results are presented in the following order: 
Firstly, section 3.1 analyses the key features of the Illumina methylation array which are 
intrinsic to the human genome and hence are the same for all samples. In particular the 
analysis investigates the distribution of CpG sites interrogated by the array, and how this 
distribution varies by the three factors, gene location, CpG island region and CpG density (as 
described in section 2).  
Section 3.2 then analyses how the distribution of CpG sites varies according to pre-treatment 
methylation levels. For this purpose, CpG sites are grouped into 10% methylation bands (i.e. 
0% to 10%, 10% to 20%, etc). At this point differences between the cell lines and patient 
samples will emerge as their pre-treatment methylation profiles are not identical. The way in 
which pre-treatment methylation levels vary across the other three intrinsic factors is also 
analysed. 
Sections 3.3, 3.4 and 3.5 analyse the levels of demethylation in all the cell lines and patient 
samples following treatment with DAC. Section 3.4 investigates how the extent of 
demethylation varies across the three intrinsic factors, and then section 3.5 extends this 
analysis by comparing demethylation levels across pre-treatment methylation groups. 
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Finally, in section 3.6 the results of regression analyses are set out, which attempt to explain 
how the level of demethylation across CpG sites varies, using the three intrinsic factors and 
pre-treatment methylation levels as explanatory variables. 
3.1 Variation in distribution of CpG sites 
The Illumina array provides methylation data for 485,577 CpG sites. After the initial filtering 
of the most unreliable probes (as described in Section 2), 479,629 CpG sites remained for 
further analysis. The following paragraphs show how the distribution of these sites varies 
across the different gene locations, CpG island regions and according to CpG density (as 
measured by the number of CpG dinucleotides in the 500bp window centred on each site, 
described in section 2). 
3.1.1 Distribution of CpG sites across gene locations 
Figure 3 below illustrates how the proportions of CpG sites on the array vary across the 
different gene locations. 
 
Figure 3 - distribution of CpG sites across gene locations 
Gene bodies contain the highest number of CpG sites, with 33.3% of the total number. 
Intergenic sites are the next highest with 24.6%. 3'UTRs have the lowest number of CpG sites 
(3.6%), followed by 1st exons (4.7%). 
33.3% 
4.7% 
3.6% 
8.8% 
14.2% 
10.8% 
24.6% 
Body 
1stExon 
3'UTR 
5'UTR 
TSS1500 
TSS200 
Intergenic 
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3.1.2 Distribution of CpG sites across CpG island regions 
Figure 4 below shows how the proportions of CpG sites on the array vary across the different 
CpG island regions. 
 
Figure 4 - distribution of CpG sites across CpG island regions 
 
Ocean regions have the largest number of CpG sites, with 36.3% of the total, followed by 
CpG islands with 31.0%. North and south shelves have the lowest numbers of CpG sites with 
5.1% and 4.6% respectively. 
3.1.3 Distribution of CpG sites across areas of different CpG density 
As described in section 2, some regions of the human genome are sparsely populated with 
CpG sites, whereas others are densely populated. Furthermore, CpG density has been shown 
to be a predictor or methylation changes when primary cells have been infected with 
oncogenic viruses
17
. Therefore, this section analyses how the numbers of CpG sites vary 
across regions of different CpG density. 
For each CpG site, the CpG density of the region in which the site is located has been 
measured as the number of CpG dinucleotides which are found in the 500bp window centred 
31.0% 
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N_Shore 
S_Shore 
N_Shelf 
S_Shelf 
Ocean 
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on the site. This measure varies between 1 and 109. Figure 5 below shows how the numbers 
of CpG sites vary across areas of different CpG density. 
 
Figure 5 - distribution of CpG sites across areas of different CpG density 
 
Most CpG sites on the array are located in regions of low CpG density. There is only a small 
proportion of CpG sites in areas of high CpG density. 
The next two sections consider how the numbers of CpG sites in each gene location and 
island region vary across areas of different CpG density. For this purpose CpG counts are 
grouped into tens (1 to 10, 11 to 20, etc), except for the final group which covers all values 
above 80. 
3.1.4 Distribution of CpG sites for each gene location, stratified by CpG density 
Figure 6 below shows, for each gene location type, how the proportions of CpG sites vary 
across the different CpG density groups.  
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It is very rare for CpG sites in any gene location to be in an area of very high CpG density 
(CpG count above 70). Gene bodies, 3'UTRs, 5'UTRs, TSS1500s and intergenic regions all 
have a large proportion of sites in areas of low CpG density (CpG count of 30 or less) - for 
example, 93% of CpG sites located in 3'UTRs are found in such areas . 1st exons and 
TSS200s have lower proportions of sites in areas of low CpG density.  
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Figure 6 - variation in distributions of CpG sites for each gene location across different CpG density groups 
 
3.1.5 Distribution of CpG sites for each CpG island region, stratified by CpG density 
Figure 7 below shows, for each CpG island region type, how the proportions of CpG sites 
vary across the different CpG density groups.  
For all CpG island regions, the proportion of sites in very high density areas (CpG count 
greater than 70) is very small. CpG sites in ocean regions, north shelves and south shelves are 
mainly located in areas of low CpG density - for example, 99% of CpG sites in north shelves 
are located in areas with a CpG count of 30 or less. North and south shores have higher 
proportions of sites in higher density areas, and islands have much higher proportions - 77% 
are located in areas with a CpG count of more than 30.  
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Figure 7 - variation in distributions of CpG sites for each CpG island region across different CpG density 
groups 
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3.1.6 Summary of key points 
 
The analysis above shows that the distribution of CpG sites varies across gene locations and 
CpG island regions. Most sites are located in areas of low CpG density, with only a very 
small proportion found in areas of high density. Within gene locations and CpG island 
regions there is variation in the proportion of sites in areas of different CpG density. 
 
3.2 Variation in pre-treatment methylation levels across CpG sites 
The three factors considered in section 3.1 are, of course, consistent across cell lines and 
patient samples. However, this is not the case for the methylation profile observed before 
treatment with DAC 
The kernel density plot in figure 8 below shows, for each cell line and patient sample, how 
pre-treatment methylation levels vary across all CpG sites on the array (note - for density 
plots the Y-axis units are arbitrary such that the area under each curve equals unity). 
 
Figure 8 - pre-treatment methylation profiles for each cell line and patient sample 
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All the cell lines and patient samples have a bi-modal distribution of methylation levels, with 
one peak at around 10% methylation and another, higher peak at around 85%. However, there 
are some differences between the profiles. These differences are summarised in table 3 below, 
which shows the average pre-treatment beta values for each cell line and patient sample. 
HL60 KGIA APAL GALWIL NALE DONCO RILNIA ZPEA CBUN ROSBOS 
59.7% 61.8% 50.6% 50.2% 52.0% 54.1% 51.7% 51.2% 48.6% 51.2% 
Table 3 - average pre-treatment beta values for each cell line and patient sample 
In particular, the average values for the two cell lines are more than 10% higher than those for 
any of the eight patient samples. Across the latter, the range is from 48.6% (CBUN) to 54.1% 
(DONCO). 
3.2.1 Average pre-treatment methylation levels stratified by gene location 
Figure 9 below shows, for each cell line and patient sample, how the average pre-treatment 
beta values vary across different gene locations. 
 
Figure 9 - average pre-treatment beta values for each gene location 
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Across all the cell lines and patient samples, 3'UTRs have the highest average pre-treatment 
beta values, followed by bodies and intergenic regions. Conversely, TSS200s have the lowest 
values, followed by 1st exons. Across all gene locations, the two cell lines have higher values 
than all of the patient samples. 
3.2.2 Average pre-treatment methylation levels stratified by CpG island region 
Figure 10 below shows, for each cell line and patient sample, how the average pre-treatment 
beta values vary across different CpG island regions. 
 
Figure 10 - average pre-treatment beta values for each CpG island region 
 
For all cell lines and patient samples, north and south shelves have the highest average pre-
treatment beta values, followed closely by ocean regions. Conversely, islands have the lowest 
values. Again the two cell lines have the highest values across all regions, with this difference 
being most pronounced for CpG islands. 
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3.2.3 Average pre-treatment methylation levels stratified by CpG density 
Figure 11 below shows, for each cell line and patient sample, the average pre-treatment beta 
values stratified by CpG density group. 
 
Figure 11 - average pre-treatment beta values for each CpG density group 
 
Across all cell lines and patient samples, there is a clear trend for reducing pre-treatment 
methylation levels as CpG density increases. The pattern is, however, less pronounced in the 
two cell lines, for which average beta value remains above 30% for all CpG density groups. 
3.2.4 Average pre-treatment methylation levels for each gene location stratified by CpG 
density 
The next two sections consider how the average pre-treatment methylation levels of CpG sites 
in each gene location and island region vary across areas of different CpG density. 
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Firstly, figure 12 below shows, for each cell line and patient sample, the average pre-
treatment beta values (y-axis) for each gene location, stratified by CpG density group. The 
trend for reducing average pre-treatment methylation level as CpG density increases can be 
seen for all gene locations. However it is less pronounced for bodies and intergenic regions, 
and more pronounced for 3'UTRs. 
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Figure 12 - average pre-treatment beta values for each gene location, stratified by CpG density groups 
 
3.2.5 Average pre-treatment methylation levels for each CpG island region stratified by 
CpG density 
Figure 13 below shows, for each cell line and patient sample, the average pre-treatment beta 
values (y-axis) for each CpG island region, stratified by CpG density group. The trend for 
reducing average pre-treatment methylation level as CpG density increases can again be seen 
for all CpG regions, although this trend is not consistent, in particular at the very highest CpG 
densities. 
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Figure 13 - average pre-treatment beta values for each CpG island region, stratified by CpG density groups 
(legend as Figure 12) 
 
3.2.6 Summary of key points 
 
The analysis of pre-treatment methylation levels shows that both cell lines and all patient 
samples have a bi-modal distribution of pre-treatment beta values, with one peak at around 
10% methylation and another higher peak at around 85%. However the distributions vary 
between cell lines and patient samples. There is also variation across gene locations and CpG 
island regions and with CpG density. Sites in areas of low CpG density tend to be highly 
methylated, whereas those in areas of high CpG density tend to have low methylation levels. 
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3.3 Changes in methylation levels following treatment with DAC 
The previous sections have shown how the distribution of CpG sites varies across gene 
locations and CpG island regions and with CpG density, and also how pre-treatment 
methylation levels  vary across samples and according to these three intrinsic factors. This 
section now looks at the changes in methylation profile after treatment with DAC. 
The extent of demethylation following treatment with DAC varied across the cell lines and 
patient samples. This variation is illustrated in  figure 14 below, which shows, for the 
different cell lines and patient samples, the distributions across all CpG sites of beta values 
both before and after treatment with DAC. 
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Figure 14 - kernel density plots of distributions of pre- and post-treatment beta values for each cell line and 
patient sample 
 
For the two cell lines and three patient samples on the left hand side (RILNIA, ROSBOS and 
ZPEA), there is a clear difference between the pre- and post-treatment methylation profiles, 
whereas for the other five patient samples on the right there is little difference. For the former, 
there is a clear overall reduction in methylation levels following treatment, whereas for the 
latter group there is virtually no change.  
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This variation is also illustrated by figure 15 below, which shows the distribution of beta 
value changes across all CpG sites for each cell line and patient sample. For example, both 
cell lines have a small peak at around 30% demethylation, followed by a higher peak centred 
around 0% demethylation. RILNIA, ROSBOS and ZPEA have similar shapes, but with 
slightly higher peaks at around 10% rather than 30% demethylation. The other five patient 
samples have a single large peak centred around 0% demethylation. 
 
Figure 15 - kernel density plot of beta value changes after treatment for each cell line and patient sample 
 
Table 4 below shows, for each cell line and patient sample, the proportions of CpG sites 
which fall into different bands of beta value change following treatment with DAC - for 
example, in the cell line HL60, 59.1% of CpG sites experienced an absolute reduction in beta 
value of at least 20% following treatment.  
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Β-change HL60 KGIA APAL GALWIL NALE DONCO RILNIA ZPEA CBUN ROSBOS 
<-20% 59.1% 58.5% 0.0% 0.0% 0.0% 0.0% 3.1% 0.7% 0.0% 2.1% 
-20 to -10% 10.4% 11.2% 0.2% 0.0% 0.3% 0.1% 27.7% 10.6% 0.0% 24.3% 
-10 to 0% 15.0% 15.6% 43.9% 31.5% 53.9% 45.4% 45.5% 55.8% 41.6% 47.0% 
0 to 10% 15.4% 14.4% 55.1% 68.2% 45.7% 54.4% 23.6% 32.8% 58.2% 26.5% 
10 to 20% 0.1% 0.2% 0.8% 0.3% 0.2% 0.1% 0.2% 0.2% 0.2% 0.0% 
>20% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Table 4 - distributions of beta value changes for each cell line and patient sample 
The two cell lines, and to a lesser extent patient samples RILNIA, ROSBOS and ZPEA, (all 
five hereafter referred to as "group 1"), have significant proportions of CpG sites which 
experienced beta value reductions of at least 10% following treatment with DAC. On the 
other hand, for patient samples APAL, GALWIL, NALE, DONCO and CBUN ("group 2"), at 
least 99% of CpG sites experienced a change in beta value (in either direction) of less than 
10%. 
Summary of key points 
 
The extent of demethylation following treatment with DAC varied between the two cell lines 
and eight patients samples. The two cell lines experienced the highest levels of 
demethylation, followed by patient samples RILNIA, ROSBOS and ZPEA. The other five 
patient samples experienced very little demethylation. 
 
3.4 Variation in demethylation levels across gene locations and CpG island 
regions and with CPG density 
The paragraphs below analyse how the changes in methylation level, for each cell line and 
patient sample, vary across gene locations, CpG island regions and with CpG density. 
3.4.1 Average change in methylation level stratified by gene location 
Figure 16 below shows the average beta values after treatment for each cell line and patient 
sample stratified by gene location. 
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Figure 16 - average post-treatment beta values for each gene location 
Comparison with figure 9 shows the extent of demethylation across gene locations. This is 
most apparent for the two cell-lines, followed by patient samples RILNIA, ROSBOS and 
ZPEA. 
Figures 17 and 18 below show the average absolute and average proportionate beta value 
reductions (i.e. a positive number represents a reduction in beta value) respectively for each 
cell line and patient sample stratified by gene location. 
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Figure 17 - average absolute beta value reductions for each gene location 
 
Figure 18 - average proportionate beta value reductions for each gene location 
For all members of group 1, there was, on average, an absolute reduction in methylation level 
after treatment across all gene locations. CpG sites located in 3'UTRs experienced the largest 
average reductions in methylation, followed closely by sites in bodies and intergenic regions. 
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Sites located in TSS200s experienced the lowest average reductions. The pattern of reductions 
across gene locations was similar when proportionate changes were considered. 
3.4.2 Average change in methylation level stratified by CpG island region 
Figure 19 below shows the average beta values after treatment for each cell line and patient 
sample stratified by CpG island region. 
 
Figure 19 - average post-treatment beta values for each CpG island region 
Comparison with figure 10 shows the extent of demethylation across CpG island regions. 
Again, this is most apparent for the two cell-lines, followed by patient samples RILNIA, 
ROSBOS and ZPEA. 
Figures 20 and 21 below show the average absolute and average proportionate beta value 
reductions respectively for each cell line and patient sample stratified by CpG island region. 
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Figure 20 - average absolute beta value reductions for each CpG island region 
 
Figure 21 - average proportionate beta value reductions for each CpG island region 
 
Again there is a consistent pattern amongst the members of group 1, and the pattern is broadly 
consistent using absolute or proportionate changes. This time, CpG sites located in north and 
south shelves experienced the largest average reductions in methylation, followed closely by 
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sites in ocean regions. Sites located in island regions had the lowest average methylation 
reductions. 
3.4.3 Average change in methylation level stratified by CpG density 
Figure 22 below shows the average beta values after treatment for each cell line and patient 
sample stratified by CpG density group. 
 
Figure 22 - average post-treatment beta values for each CpG density group 
Comparison with figure 11 shows the extent of demethylation across CpG density groups. 
Once again, this is most apparent for the two cell-lines, followed by patient samples RILNIA, 
ROSBOS and ZPEA. 
Figures 23 and 24 below show the average absolute and average proportionate beta value 
reductions respectively for each cell line and patient sample stratified by CpG density group. 
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Figure 23 - average absolute beta value reductions for each CpG density group 
 
Figure 24 - average proportionate beta value reductions for each CpG density group 
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For all five members of group 1 there is a clear trend for the absolute reduction in methylation 
level to decrease as CpG density increases. However, for the two cell lines the trend flattens 
out at an absolute beta value reduction of just under 10% for the higher CpG densities (CpG 
count greater than 60), whereas it continues sharply downwards for RILNIA, ROSBOS and 
ZPEA. The pattern of proportionate changes is similar to that for absolute changes, although 
at higher CpG densities some small proportionate increases are observed in the patient 
samples. CpG sites with high CpG densities tend to have low pre-treatment beta values, so 
some care is required in interpreting these proportionate changes. 
The next two paragraphs consider how the average reductions in methylation level of CpG 
sites in each gene location and island region vary across areas of different CpG density. 
3.4.4 Average change in methylation level for each gene location stratified by CpG 
density 
Figure 25 below shows, for each cell line and patient sample, the average beta value 
reductions (y-axis) for each gene location, stratified by CpG density group. The trend for 
decreasing average methylation reductions as CpG density increases is present across all gene 
locations. However, it is less pronounced in bodies, 3'UTRs and intergenic regions. Also, as 
previously noted, the trend flattens out in the two cell lines at higher CpG densities across all 
gene locations. 
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Figure 25 - average beta value reductions for each gene location, stratified by CpG density group 
 
3.4.5 Average change in methylation level for each CpG island region stratified by CpG 
density 
Figure 26 below shows, for each cell line and patient sample, the average beta value 
reductions (y-axis) for each CpG island region, stratified by CpG density group. The general 
trend for decreasing average methylation reductions as CpG density increases is again present 
across all CpG island regions. However, this trend is not entirely consistent, for example at 
higher CpG densities in both north and south shelves. 
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Figure 26 - average beta value reductions for each CpG island region, stratified by CpG density group (legend 
as Figure 25) 
 
3.4.6 Summary of key points 
 
The analysis above shows that the level of demethylation varies across gene locations and 
CpG island regions and with CpG density. In particular, it appears to be inversely correlated 
to CpG density, and this pattern is also seen when the analysis is broken down by both gene 
location and island region. Analyses by both absolute and proportionate changes show similar 
patterns of demethylation. 
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3.5 Variation in changes in methylation levels following treatment with 
DAC across pre-treatment methylation levels 
This section considers how average reductions in methylation level vary across CpG sites 
according to pre-treatment methylation level, with further stratification by gene location, CpG 
island region and CpG density. 
3.5.1 Average change in methylation level stratified by pre-treatment methylation level 
Figure 27 below shows the average beta values after treatment for each cell line and patient 
sample stratified by pre-treatment beta value group. 
 
Figure 27 - average post-treatment beta values for each pre-treatment beta value group 
 
The extent of demethylation across pre-treatment beta value groups is most apparent for the 
two cell-lines, followed by patient samples RILNIA, ROSBOS and ZPEA. 
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Figures 28 and 29 below show the average absolute and average proportionate beta value 
reductions respectively for each cell line and patient sample stratified by pre-treatment beta 
value group. 
 
Figure 28 - average absolute beta value reductions for each pre-treatment beta value group 
 
Figure 29 - average proportionate beta value reductions for each pre-treatment beta value group 
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Across all five members of group 1, there is a very clear trend of increasing reduction in 
methylation level as pre-treatment methylation level increases. This is observed for both 
absolute and proportionate changes, although the pattern is less pronounced for the latter. 
3.5.2 Average change in methylation level for each gene location stratified by pre-
treatment methylation levels 
Figure 30 below shows, for each cell line and patient sample, the average beta value 
reductions (y-axis) for each gene location, stratified by pre-treatment beta value group.  
For all five members of group 1 the trend for increasing demethylation as pre-treatment 
methylation level increases remains clear, and this pattern is similar across all the different 
gene locations. 
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Figure 30 - average beta value reductions for each gene location, stratified by pre-treatment beta value group 
(legend as Figure 27) 
3.5.3 Average change in methylation level for each CpG island region stratified by pre-
treatment methylation levels 
Figure 31 below shows, for each cell line and patient sample, the average beta value 
reductions (y-axis) for each CpG island region, stratified by pre-treatment beta value group. 
For all five members of group 1 the pattern of increasing demethylation with increasing pre-
treatment methylation level is again clear, and this pattern is similar across all the different 
island region types. 
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Figure 31 - average beta value reductions for each CpG island region, stratified by pre-treatment beta value 
group (legend as Figure 27) 
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3.5.4 Average change in methylation level for each CpG density group stratified by pre-
treatment methylation levels 
Figure 32 below shows, for each cell line and patient sample, the average beta value 
reductions (y-axis) for each CpG density group, stratified by pre-treatment beta value group. 
For both cell lines the trend for increasing demethylation with increasing pre-treatment 
methylation level is again clear. This is also true for the other three members of group 1, but 
the pattern does appear to break down at the highest CpG densities. This is particularly the 
case for ROSBOS in the highest CpG density category, where the average beta value 
reduction is around 25% for the 80-90% pre-treatment methylation group, but only around 
15% for the 90-100% group. 
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Figure 32 - average beta value reductions for each CpG density group, stratified by pre-treatment beta value 
group (legend as Figure 27) 
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3.5.5 Conclusion so far 
The analysis in this section has so far shown that pre-treatment methylation level appears to 
be the dominant factor in determining the extent to which a CpG site will be demethylated 
following treatment with DAC. However, the analysis in paragraph 3.5.4 suggests that there 
may also be a secondary effect associated with CpG density. In order to investigate this 
possibility further, paragraph 3.5.6 considers the analysis in 3.5.4 in the reverse order of 
stratification. 
3.5.6 Average change in methylation level for each pre-treatment beta value group stratified 
by CpG density group 
Figure 33 below shows, for each cell line and patient sample, the average beta value 
reductions (y-axis) for each pre-treatment beta value group, stratified by CpG density group. 
When the stratification is performed this way round, the variation across CpG density groups 
for any given pre-treatment beta value group is small. However, there is still some variation, 
in particular for CpG sites in the 40%-60% pre-treatment beta value range. Hence, whilst pre-
treatment methylation level appears to have the most dominant association with 
demethylation, it is also possible that there is a secondary association with CpG density. 
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Figure 33 - average beta value reductions for each pre-treatment beta value group, stratified by CpG density 
group (legend as Figure 25) 
 
3.5.7 Summary of key points 
 
The analysis above shows that there is a very clear trend of demethylation increasing with 
increasing pre-treatment methylation level. This trend is apparent for both absolute and 
proportionate changes, although it is most clear for absolute changes. Once the trend is taken 
into account, the other three factors have little further impact on the level of demethylation, 
although there is some evidence that CpG density may have a small, additional effect.  
 
3.6 Predictors of methylation change  
Section 3.3 above identified that both cell lines and three of the patient samples experienced 
demethylation following treatment with DAC, whereas the other five patient samples 
experienced very little demethylation. For the former group, this section analyses the factors 
which may predict how the level of demethylation varies across different CpG sites. 
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3.6.1 Pre-treatment methylation level is the main predictor of demethylation 
The results in section 3.5 suggest that the principal determinant of the extent to which a 
particular CpG site will be demethylated following treatment with DAC is the site's pre-
treatment methylation level.  
In order to formally confirm the conclusion reached in section 3.5, a linear regression analysis 
was performed. For this purpose, absolute beta value change was the predicted outcome, and 
pre-treatment beta value, gene location, CpG island region and CpG density (as measured by 
CpG count) were the candidate predictor variables. For the five members of group 1, the 
correlations (R
2
) identified by this analysis are set out in table 5 below. 
Variables used HL60 KGIA RILNIA ROSBOS ZPEA 
      
Pre-treatment beta value alone 0.846 0.825 0.657 0.669 0.540 
Pre-treatment beta value and CpG density 0.846 0.826 0.660 0.672 0.561 
Pre-treatment beta value and gene location 0.846 0.826 0.658 0.671 0.543 
Pre-treatment beta value and island region 0.846 0.826 0.658 0.671 0.551 
Table 5 - R
2
 values for associations of factors with absolute beta value change 
For all five, this analysis shows that a significant proportion of the variation in demethylation 
levels between CpG sites is explained by pre-treatment methylation level, and that the other 
three candidate variables add very little to this association. The results are most striking for 
the two cell lines, which experienced the greatest levels of demethylation. 
For the other five patient samples, the associations between each of the candidate variables 
and beta value change are very small (maximum R
2
 of 12.8%). 
If proportionate changes are considered instead of absolute changes, the levels of association, 
as set out in table 6 below, are lower but follow a similar pattern to table 5. 
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Variables used HL60 KGIA RILNIA ROSBOS ZPEA 
      
Pre-treatment beta value alone 0.581 0.527 0.281 0.370 0.261 
Pre-treatment beta value and CpG density 0.581 0.528 0.283 0.370 0.274 
Pre-treatment beta value and gene location 0.581 0.528 0.281 0.370 0.263 
Pre-treatment beta value and island region 0.582 0.528 0.282 0.370 0.269 
Table 6 - R
2
 values for associations of factors with proportionate beta value change 
Given that absolute changes are correlated with pre-treatment methylation levels, one might 
expect that the correlation between proportionate changes and pre-treatment methylation 
levels would be lower. However, there is still a correlation meaning that proportionate 
changes are not independent of pre-treatment methylation levels. Also, the analysis using 
proportionate changes is possibly subject to greater distortion caused by measurement 
inaccuracy. 
3.6.2 Logistic regression analysis of factors affecting demethylation 
In order to further analyse the associations between the four candidate variables and level of 
demethylation, a logistic regression analysis was performed. For this purpose, the outcome to 
be predicted for each CpG site was whether the site was demethylated following treatment 
with DAC. Two separate thresholds for the absolute reduction in beta value were used to 
determine whether a site had been demethylated: 
 20% - in the literature, a 20% cut-off has typically been used to test whether a site is 
demethylated - i.e. a site's beta value must have reduced by at least 20%. This is based 
on an analysis by Bibikova, which stated that a 20% absolute change could be detected 
with 99% confidence by the Illumina array. 
 10% - as mentioned in section 2.5, this study has found that 99.5% of all pairs of 
replicate beta value measurements using the Illumina array were within 10% of each 
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other. Therefore, it could reasonably be argued that a 10% absolute change could be 
used as an alternative threshold. 
As illustrated in section 3.3, using a 20% cut-off is very restrictive for all the patient samples 
(as only a very small proportion of CpG sites experienced demethylation of at least 20%), and 
the logistic regression analysis produced very small associations between all of the four 
candidate variables and demethylation. However, a 20% threshold is a lot less restrictive for 
the two cell lines (each having around 59% of sites which were demethylated by at least 
20%), and for these samples the logistic regression found strong associations between 
demethylation and pre-treatment beta value (Nagelkerke's R
2
 values of 0.748 and 0.729 for 
the cell lines HL60 and KGIA respectively). Introducing the other other three variables into 
the regression analysis only increased these values by very small amounts (maximum 0.001). 
A 10% threshold is less restrictive, especially for patient samples RILNIA and ROSBOS. 
Table 7 below shows the associations (measured by Nagelkerke's R
2
) for both cell lines and 
RILNIA, ROSBOS and ZPEA. 
Variables used HL60 KGIA RILNIA ROSBOS ZPEA 
      
Pre-treatment beta value alone 0.858 0.877 0.421 0.356 0.140 
Pre-treatment beta value and CpG density 0.863 0.880 0.423 0.360 0.157 
Pre-treatment beta value and gene location 0.858 0.877 0.423 0.359 0.143 
Pre-treatment beta value and island region 0.861 0.879 0.422 0.358 0.148 
Table 7 - Nagelkerke's R
2
 values for associations of factors with beta value change 
Whilst the associations for RILNIA, ROSBOS and, in particular, ZPEA are a lot smaller than 
those for the two cell lines, there is still a clear pattern of pre-treatment methylation level 
having the strongest association with demethylation, with the other three variables adding 
very little.  
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3.6.3 Stratification of average methylation change by pre-treatment methylation level 
Table 8 below shows how the average absolute reduction in beta value, for each cell line and 
patient sample, varies according to pre-treatment beta value (grouped into 10% ranges). 
 HL60 KGIA RILNIA ROSBOS ZPEA APAL GALWIL NALE DONCO CBUN 
90%-100% 39.2% 36.0% 16.4% 15.4% 12.1% -0.1% 0.3% 3.3% 1.2% 1.3% 
80%-90% 32.0% 29.5% 12.0% 11.2% 7.5% -0.7% -0.8% 1.7% 0.4% 0.4% 
70%-80% 27.1% 25.0% 9.7% 9.1% 5.4% -1.7% -2.0% 0.5% -0.6% -0.8% 
60%-70% 21.0% 19.0% 6.9% 6.4% 3.0% -2.3% -2.4% -0.4% -0.8% -1.4% 
50%-60% 15.4% 14.5% 4.4% 3.5% 1.0% -1.4% -2.0% -0.5% -1.0% -1.8% 
40%-50% 10.7% 10.9% 2.7% 1.8% 0.1% -0.6% -2.0% -0.8% -1.2% -2.2% 
30%-40% 7.3% 7.6% 2.0% 1.0% -0.8% 0.2% -1.6% -0.8% -1.1% -2.0% 
20%-30% 3.8% 3.2% 0.7% 0.2% -1.4% 0.7% -1.0% -0.7% -0.7% -1.2% 
10%-20% -0.7% -0.7% -0.6% -0.6% -1.2% 0.5% -0.6% -0.6% -0.5% -0.4% 
0%-10% -0.8% -0.4% -0.5% -0.5% -0.5% 0.1% -0.3% -0.5% -0.5% -0.3% 
Table 8 - average reductions in beta values broken down by pre-treatment beta value groups 
For all five members of group 1 this table shows a clear association between pre-treatment 
methylation level and the extent of demethylation following treatment with DAC. 
3.6.4 Possible secondary association with CpG density 
Section 3.5.6 suggested that there may be a secondary association of methylation change with 
CpG density for sites whose pre-treatment methylation levels are in the 40% to 60% range. In 
order to test this, a linear regression was performed for sites in this range. Taking the HL60 
cell line as an example, the regression showed that for sites in this range, pre-treatment 
methylation level and CpG density had very similar correlations with the level of methylation 
change (R
2
 values of 17.2% and 16.0% respectively). Similar results were obtained for the 
KGIA cell line and patient samples RILNIA, ROSBOS and ZPEA. The analysis also showed 
that there was no interaction between CpG density and pre-treatment methylation level. 
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3.6.5 Summary of key points 
 
The key result from this analysis is that, of the factors analysed in this study, pre-treatment 
methylation level is by far the most important in predicting the extent to which a particular 
CpG site will be demethylated following treatment with DAC. This is observed for both 
absolute and proportionate changes, although the correlations are lower for proportionate 
changes (possibly in part because of the potential inaccuracy in using proportionate changes). 
There also appears to be a secondary association with CpG density for CpG sites whose pre-
treatment methylation levels are in the range 40% to 60%. However, for the patient samples 
in particular, a lot of variation in demethylation levels is still unexplained. 
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4. Discussion 
The analysis  showed considerable variation in the level of demethylation between samples. 
In particular, the two cell lines and three of the patient samples were demethylated to a much 
greater extent than the other five patient samples. Within samples, CpG demethylation was 
found to vary according to gene location, CpG density, CpG island region and pre-treatment 
methylation level. Multivariate regression analysis showed that of the factors investigated, the 
principal determinant of demethylation at an individual CpG site was the pre-treatment 
methylation level (high pre-treatment methylation implies high reduction and vice-versa). 
The principal correlation between pre-treatment methylation level and level of demethylation 
following treatment was observed when both absolute and proportionate methylation changes 
were considered. Although the correlation was lower for the latter case, it was still evident 
meaning that proportionate changes in methylation are not independent of pre-treatment 
methylation level. It should also be noted that the use of proportionate changes is potentially 
subject to distortion caused by measurement inaccuracy. 
The level of demethylation also appeared to be inversely correlated to CpG density. However 
the stratification by CpG density and starting beta value clearly demonstrated that the latter 
has by far the greater impact. CpG density still has an effect, but this is much smaller and 
tends to be concentrated in the 40% to 60% pre-treatment beta value range.  
Once the effect of pre-treatment methylation level is allowed for, there is no obvious 
association of beta value change to gene location, whilst, as might be expected, there is a high 
correlation of CpG density to CpG island region, meaning that the latter does not appear to 
have any additional, independent influence. 
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It is possible that the primary association with starting beta value can be at least partially 
explained by the effect known as "regression to the mean" - i.e. some of the higher pre-
treatment beta values may have been overstated (by measurement error), so a subsequent re-
measurement is likely to be lower (i.e. nearer the correct value) and vice-versa
18
. Cost 
considerations meant that it was not possible to process technical replicates of the AML 
samples using the Illumina array, so the precision of the measurements could not be tested 
directly. However a further analysis was performed using the same array and in the same 
laboratory  on a completely independent data set which did include technical replicates. 
Comparison of the methylation measurements between replicates suggested that regression to 
the mean is not an issue. Also, the distribution of results for the other five patient samples 
gave no indication that regression to the mean is having a material impact on the results. 
The key, most directly comparable previous research into this area is covered in the paper by 
Hagemann et al
11
. That study also found that demethylation following treatment with DAC is 
dependent on pre-treatment methylation level, and also that CpG sites in CpG islands were 
less likely to be demethylated. However, this project was able to provide a more refined 
analysis - for example, the Hagemann paper was based on the older version of the Infinium 
technology
19
 which, in particular, interrogated around 28,000 CpG sites compared with over 
480,000 sites analysed by the newer technology used for this project. 
It is also important to stress that the analysis in the Hagemann paper was based exclusively on 
cell lines. It may be unwise to extrapolate results observed from cell lines to human samples. 
Indeed, this project has shown that demethylation in the two cell lines was greater than in all 
eight patient samples, and that there was substantial variation across the patient samples.  
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The results are also consistent with other research by Rubinstein et al
20
, which investigated 
the effect of DAC on gene expression levels in melanoma cell lines and looked at the 
associations with pre-treatment methylation levels and CpG content. Rubinstein found that 
gene promoters with high pre-treatment methylation levels and intermediate CpG content 
appeared most susceptible to up-regulation following treatment with DAC.  
Recent research by Yan et al
21
, which used methylated DNA capture in combination with next 
generation sequencing to investigate the effect of DAC treatment on genome-wide 
methylation levels of 16 AML patients aged over 60, also found that the extent of 
demethylation appears to be correlated to pre-treatment methylation levels. Consistent with 
this project, and confirming the heterogeneity which exists between patients, the Yan study 
also showed considerable variation in demethylation between samples. There was significant 
demethylation observed in the nine patients who achieved complete remission following 
treatment with DAC, whereas the other seven patients who did not achieve complete 
remission showed no significant changes in methylation.  
However, the Yan study also showed that demethylation occurred mainly in CpG island 
regions, which is in contradiction to the results of this project. Hence one area of future work 
would be to investigate the reasons for this apparent discrepancy. 
Another area where further work should be pursued is to look at the mechanisms by which 
DAC causes demethylation. The Hagemann paper
11
 includes some results on this. Firstly, it 
identified that CpG sites associated with genes involved in the Polycomb Repressive Complex 
2 appeared to be more resistant to demethylation  than other CpG sites. Secondly, it identified 
that demethylation-sensitive and demethylation-resistant CpG sites showed complementary 
enrichment of certain transcription factor binding sites. Recent research by Metzeler et al
22
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has also linked reduced expression of DNMT3A in AML patients to response to DAC. Hence 
these are areas which would be worth investigating further. 
There are a number of areas in which this project could be improved. Firstly, one potential 
cause of the variation in demethylation across the samples is the timescale used. The post-
treatment methylation measurements were performed five days after treatment for all samples. 
Hence the results simply reflect a snapshot of demethylation levels at  a single point in time. 
Primary samples grown in vitro do not all proliferate at the same rate. The variation in 
demethylation among the samples is likely to reflect these differences in proliferation, with 
the faster dividing cells demethylating to a greater extent than the slower growing cells.  It is 
possible that if further measurements had been taken at different time-points, then different 
methylation patterns would have been observed.  
Secondly, because AML is rare in children, it is difficult to obtain samples from paediatric 
patients. Hence the analysis was based on a small number of samples, which means that any 
conclusions are potentially biased by the particular characteristics of the samples and would 
need to be confirmed in a larger group of samples. 
Finally, the Infinium HumanMethylation450 BeadChip technology is relatively new, having 
been released in 2011. There are a number of papers which attempt to investigate the accuracy 
of the technology
23,24,25,26
, but there is still no clear consensus on the best approach for 
downstream analysis of the output. For example, Touleimat
26
 considered eight different 
methods for processing the raw Illumina data, and compared the results for a small sample of 
CpG sites against a separate analysis using pyrosequencing, but did not show conclusively 
that any one method was superior to the others.  Hence, whilst there is no obvious evidence of 
inaccuracy, and this was corroborated by the pyrosequencing analysis used for this project, it 
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would be desirable for further investigation of the technical accuracy of the Illumina array to 
be carried out. 
In conclusion, this project has shown that pre-treatment methylation level appears to be the 
main determinant of the extent to which an individual CpG site will be demethylated 
following treatment with DAC. However, the analysis also showed that the determinants 
identified were in themselves insufficient to explain all of the variation in demethylation 
observed across study samples. Further work with larger sample sizes is required to validate 
this result and to help elucidate the mechanisms by which DAC operates. 
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 Abstract 
In recent years new "omic"-based technologies, such as microarrays, have been used to create 
many novel biomarker models for predicting outcomes in human cancer. However, only a 
fraction of these models have been put into actual clinical use. For models to have proven 
value, they must be shown to be generalisable to the wider population away from the data sets 
used to create them. To achieve this models must be properly validated. Various studies have 
considered how such validation should be performed.  
 In this study, a survey has been undertaken of 100 recent papers which have claimed to have 
validated "omic"-based biomarker models. The purpose of the study was to compare actual 
validation methodologies being used against best practice as set out in the literature. The 
results show that there are considerable deficiencies in the way that validation is undertaken, 
in particular with regard to sample sizes which are too small, inappropriate handling of data 
and over-reliance on validation methods which do not use genuinely independent data. Also, 
there is a disappointing shortage of studies undertaking independent validation of models 
constructed by other research teams. 
In conclusion, more emphasis is required on the proper validation of biomarker models. 
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1.  Introduction 
This project surveyed recent scientific literature concerning the validation of models created 
for predicting outcomes in human cancer using biomarker data derived from the various 
"omic"-based technologies (i.e. genomics, transcriptomics, proteomics, metabolomics and 
epigenomics). 
1.1 Background 
In the last few years, technological advancements (such as microarrays) have made it possible 
for researchers to quickly and efficiently analyse large amounts of biological data. One of the 
key uses these technologies have been put to is to try to make diagnostic or prognostic 
predictions in relation to outcomes in cancer (e.g. probability of getting cancer, probability of 
metastasis etc) based on "omic" biomarker data extracted from actual human samples. 
Many scientific papers have been published claiming to have produced novel "omic"-based 
models for use in cancer prediction
1
. However, only a very small proportion of these models 
have actually been approved for clinical use
2
. Not only is this an inefficient use of scientific 
resources, but it could also be argued to be detrimental to overall scientific knowledge as the 
literature becomes cluttered with large numbers of papers which have minimal, if any, 
practical usefulness. 
1.2 The key problems 
There are several potential issues which can limit the usefulness of a newly-created biomarker 
model. These issues can be broken down into the following broad categories
2,3
: 
1. Incorrect or inappropriate use of technology by which the raw data are extracted 
2. Inappropriate experimental design 
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3. Inappropriate mathematical / statistical techniques used for analysing the raw data and 
creating the model 
4. Lack of suitable validation of the model once it has been created 
5. Lack of translatability into actual clinical use 
This project concentrates on the fourth of these areas, whilst also touching on the third and 
fifth.  
The key issue which this project considers is that, whilst a model might appear to have very 
good predictive value when applied to the data on which it is based, it is essential that the 
results are confirmed in a separate analysis using an independent data set. A check on the 
results provides a test of whether the model is generalisable to the wider population, or 
whether it is overfitted to the data on which it is based - i.e. rather than identifying genuine 
biological differences in the selected biomarkers which are present in the whole population, it 
also simply reflects particular characteristics of the samples used to create it
1
. Overfitting is a 
common problem with predictive models, and although it can be improved by using large 
sample sizes
4
, often cost issues and the scarcity of suitable data make this difficult to achieve 
in practice. 
1.3 The solution - validation 
In order to overcome the problem of overfitting, it is imperative for a model to be validated. 
Validation should ideally be performed on (at least one, but preferably several) completely 
independent, external data sets - hereafter referred to as "external validation"
3
. Such 
validation will test the generalisability of the model to the wider population. 
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In practice, other validation techniques are also used which do not make use of external data 
sets but are instead based on the data set used to create the model - hereafter referred to as 
"internal validation"
3
. This can involve the splitting of the data into a "training" set used to 
create the model and a "validation" set used to test its performance. The crucial point here is 
that both sets of data have come from the same source, and are therefore not genuinely 
independent, even if they contain different samples.  
Internal validation also includes such techniques as cross-validation and permutation testing. 
Cross-validation is a frequently used method for assessing the predictive accuracy of a model 
without using any additional data. Typically, the entire training dataset is split randomly into 
two subsets. The first, usually larger, of these subsets  is used to train the model using exactly 
the same methodology as was used for the entire data set. This (sub-) model is then tested on 
the second subset of data. The process is repeated several times and the average performance 
across all random splits of the data is used to assess the overall predictive performance of the 
model.  
The relative sizes of the subsets can vary - for example, at one extreme (known as leave-one-
out-cross-validation, or "LOOCV") the training subset includes all bar one of the members of 
the full data set, and is used to train a model which is then tested on the one excluded 
member, this process then being repeated with every member of the full data set treated in 
turn as the test member. Other variants used are known as k-fold where the full data set is 
randomly split into k subsets of equal size, and then each of these subsets in turn is used as the 
testing subset with the other k-1 used together as the training subset. 
Another technique often used to assess the statistical significance of a model's performance 
(i.e whether a model is predictive, rather than how accurate its predictions are), is the use of 
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permutation testing. Once a model has been used and the results obtained, the significance of 
the results can be estimated by repeatedly, randomly reassigning all the samples to the 
observed outcomes and recalculating the relevant performance statistics on the permuted data. 
If this process is performed a large number of times, then the significance of the model 
performance can be estimated by ranking all the permuted results and finding where the actual 
result based on the actual, unpermuted data, falls within these rankings. Based on 10,000 
permutations for example, if the actual result falls within the extreme 500 most results then it 
could be said that the result is significant at the 5% level. 
Previous research has found that internal validation techniques, whilst preferable to 
undertaking no validation at all, are not as successful as external validation at accurately 
gauging the generalisability of a model - the key issue being that they tend to overestimate the 
performance of the model
5
. 
1.4 How to assess model performance 
Whatever validation methodology is used, there are two critical areas of performance of the 
model which should be tested. These are "calibration" and "discrimination"
3
. Calibration 
compares the frequency of predicted and actual outcomes, whilst discrimination measures the 
model's ability to distinguish between patients with and without a particular outcome.  
There are various statistical techniques available to assess both of these measures. For 
example, calibration can be assessed by comparing observed proportions of events against 
predicted probabilities. For discrimination, the standard statistical measures of sensitivity and 
specificity can be calculated, along  with the area-under-the-curve (AUC) of the receiver 
operating characteristics curve (ROC). 
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For a model to actually be approved for clinical use, a cost-benefit analysis of applying the 
model in practice needs to be made
2
. Such an analysis would compare the benefits from 
making a correct prediction using the model with the costs of making an incorrect decision. 
For example, diagnosing the presence of a particular cancer may result in some form of 
exploratory surgery. Clearly if the diagnosis is correct, then the surgery is worthwhile and 
there is a huge benefit to the patient. However, there will be a (hopefully very small) 
proportion of patients for whom the diagnosis is incorrect, leading to unnecessary surgery. If 
the overall costs of unnecessary surgery outweigh the benefits of correct diagnoses, then it 
might be considered  inappropriate to use the model even if a correct diagnosis is of huge 
benefit to the individuals concerned. 
1.5 Aims of project 
Given the importance of proper validation of newly created biomarker models, the key aims 
of this project were to: 
 systematically review recent scientific literature to survey the validation 
methodologies used in practice. The survey was focused on models which were 
created using "omics"-based data, which were intended to be used for predicting 
outcomes relating to human cancer, and which had been subject to validation in some 
form; 
 document and summarise the ways in which validation was undertaken - e.g. 
methodology used, sample sizes; 
 compare actual practice with what is known about validation methodology best 
practice from relevant scientific literature; 
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 where the information was available, compare measures of model performance based 
on different validation methodologies. 
A literature review was undertaken to capture the most recent 100 scientific papers which 
involved the validation of such biomarker models. Relevant items of data were extracted from 
each of these papers, and then analysed.  
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2. Data and methods 
There were four key stages to this project: 
 literature search to identify potential papers 
 filtering process to select most recent 100 papers meeting inclusion criteria 
 establishment of database of answers to pre-specified questions 
 analysis of database and comparison of findings against best practice 
Each of these stages is considered in turn below. 
2.1 Literature search 
The first part of this project was the literature search. The purpose of the search was to find 
papers which were relevant to the project according to the following three criteria: 
1. They each involved the validation of a predictive, mathematical model. 
2. The primary outcome being predicted involved some aspect of human cancer. 
3. The model used "omic"-based biomarkers. 
The search was performed on 7 May 2012 using the biomedical literature database Medline, 
which was accessed on-line via the University of Birmingham's e-Library facility. Table 1 
below shows how each of the three criteria mentioned above were allowed for in the search 
command (note: at this stage, validation was not included in the search as this was found to be 
too restrictive): 
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Criterion Search string Location 
searched 
Medline search command 
    
1. "predict*" or "prognos*" Title "predict*".m_titl.   
OR 
"prognos*".m_titl. 
 
2. "cancer"  
OR  
"cancer" or "Neoplasms" (all sub-
headings) 
 
Title 
 
Keywords 
cancer.m_titl. 
OR 
cancer.mp.or exp 
Neoplasms/ 
3.  "genom*", "epigenom*", 
"transcriptom*", "proteom*", 
"metabolom*" or "gene*"  
Title "genom*".m_titl. 
OR 
"epigenom*".m_titl. 
OR 
"transcripto*".m_titl. 
OR 
"proteom*".m_titl. 
OR 
"metabolom*".m_titl. 
OR 
"gene*".m_titl. 
    
The final search command combined all of these three commands with the "AND" operator. 
 Table 1 - details of literature search command using Medline biomedical database 
2.2 Filtering process 
The search using the above commands identified 3,190 papers. A filtering process was then 
undertaken, applied to the papers in reverse chronological order, until 100 papers which 
satisfied all requirements had been selected. The requirements for each paper were: 
 It was written in English. 
 It was not a review article. 
 It had an abstract. 
 The abstract included clear indication that all of the three criteria mentioned in section 
2.1 were met - in particular that validation had been performed. 
 The paper was available for download via the University of Birmingham's e-Library. 
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2.3 Establishment of database 
Once 100 papers had been identified, the next stage was to extract relevant information from 
each of the papers and to store this in a database. A set of questions was devised, as outlined 
below, and then each of the papers was studied in turn, with the answers to each question 
being recorded in a database created using Microsoft Excel. 
The questions applied to each paper were subdivided into four main categories, which were: 
 Background information about the paper. 
 Information about the model-building process. 
 Information about any internal validation process which had been undertaken. 
 Information about any external validation process which had been undertaken. 
The questions which were asked under each category were as follows:- 
2.3.1 Background information 
A small number of questions were asked to gain an understanding of the background of the 
100 papers. These are set out in table 2 below: 
1. In which year was the paper published? 
2. In which country was the primary author based? 
3. What type of cancer was the subject of the paper? 
4. The paper was based on which of the "omics"? 
5. Did the paper cover both the creation and validation of a model, or just the validation 
of an existing model? 
6. Was the model to be used for diagnostic, prognostic or predictive purposes? 
Table 2 - questions relating to background information 
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The final question was used to identify whether the purpose of the model was to: 
 make a diagnosis - e.g. whether someone had cancer; or 
 make a prognosis - e.g. how long would someone already with cancer be expected to 
live; or 
 make a prediction of the impact of treating someone in a particular way - e.g. how 
long would someone be expected to live if they were treated using chemotherapy? 
The possibility that some models might include more than one of these options was allowed 
for. In this case, the questions in the other three categories, as described below, were applied 
separately for each aspect of the model. 
2.3.2 Model-building process 
The next part of the questionnaire concerned aspects of the model-building process. These 
questions were used to identify key issues which have been shown to affect the usefulness of 
biomarker-based models and to enable comparison of any performance statistics with 
validation results. The questions considered how the data were gathered, sample sizes, the 
numbers and types of biomarkers, details of the final model, and key performance measures. 
The questions posed are set out in table 3 below: 
1. Was the model based on a prospective or retrospective study? A model was deemed 
to be based on a retrospective study if it was clear from the paper that it was based 
on the use of an old data set. Alternatively, it was deemed to be prospective if it was 
clear that patients had been genuinely prospectively recruited and the data had only 
recently been extracted. If there was any doubt an answer of "unclear" was recorded. 
2. If prospective, was the study planned for use in the model-building exercise, or did 
the model-building make opportunistic use of a study originally designed for another 
purpose? If there was any doubt then an answer of "unclear" was recorded. 
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3. What was the key outcome considered by the model (e.g. death from any cause, 
recurrence-free survival)?  
4. What type of biomarker variable was used in the model - e.g. was it a continuous, 
numerical value (such as gene expression level), or a binary amount (such as 
presence of absence of a particular genetic mutation)? 
5. In the initial selection of biomarkers to include in the model, was any explicit 
adjustment made to control false discovery rates? 
6. Was a completely separate data set used solely for the purposes of conducting an 
initial filtering of biomarkers to be used in the subsequent model-building? 
7. How many biomarkers were used in the model-building exercise? 
8. How many biomarkers were used in the final model? 
9. Samples from how many patients were used in the model-building exercise? 
10. Were any patient samples removed from the initial data set because of unavailable 
information? 
11. How many "outcomes" were observed amongst the patients (e.g. if the key outcome 
under consideration was death from any cause, how many patients died?) 
12. Was the validation data set (if there was one) used in any part of the model-building 
exercise? 
13. Was the final rule created by the model explicitly stated? 
14. Did the model split patients into groups (e.g. high or low risk), and, if so, how many? 
15. What method was used to determine the split into groups? 
16. Was the calibration of the model measured? 
17. If so, what method was used? 
18. Were specificity and sensitivity measured? 
19. If so, what were their values? 
20. Was the AUC measured? 
21. If so, what was its value? 
22. Were any other discrimination measures reported? 
23. Was any decision analysis performed? 
Table 3 - questions relating to model-building process 
 
12 
 
2.3.3 Internal validation process 
The next section of the questionnaire included the questions in table 4 below which were 
asked to identify key issues concerning any internal validation performed on each model: 
1. Was internal validation with a split of the data set (into training and validation parts) 
used? 
2. If so, how was the data set split? 
3. How many patients were in the validation part of the data set? 
4. And how many outcomes were observed amongst these patients? 
5. Was any cross-validation used? 
6. If so, what technique was used (e.g. leave-one-out-cross validation, two-fold etc) 
7. And what was the key purpose of the cross-validation? 
8. Did the cross-validation include the biomarker selection process? 
9. Was permutation testing used? 
10. If so, how many permutations? 
11. And what was the key purpose of the permutation testing? 
12. Was the calibration of the model measured? 
13. If so, what method was used? 
14. Were specificity and sensitivity measured? 
15. If so, what were their values? 
16. Was the AUC measured? 
17. If so, what was its value 
18. Were any other discrimination measures reported? 
Table 4 - questions relating to internal validation  process 
The key purposes of asking these questions were to identify how commonly each type of 
internal validation was used, how they were applied in practice, the sample sizes on which the 
validation was undertaken (where appropriate), and the frequency of reporting of key 
performance measures and their actual values for comparison with corresponding figures from 
the model-building process. 
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2.3.4 External validation process 
Finally, the following similar group of questions, as set out in table 5 below, were asked to 
identify key issues concerning any external validation performed on each model: 
1. Was any external validation performed? 
2. If so, was the validation data set based on a prospective or retrospective study? 
3. If prospective, was the study planned for use in the validation exercise, or did the 
validation make opportunistic use of a study originally designed for another purpose? 
4. How many independent data sets were used? 
5. Samples from how many patients were used? 
6. Were any patient samples removed from the initial data set(s) because of unavailable 
information? 
7. How many "outcomes" were observed amongst the patients? 
8. Were the patients taken from the same location as those used for the model-building? 
9. Was the validation data gathered by someone other than the research team who 
originally produced the model? 
10. Was the calibration of the model measured? 
11. If so, what method was used? 
12. Were specificity and sensitivity measured? 
13. If so, what were their values? 
14. Was the AUC measured? 
15. If so, what was its value? 
16. Were any other discrimination measures reported? 
Table 5 - questions relating to external validation  process 
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2.4 Analysis of database 
Once the database had been constructed, the final stage of the project was to analyse the data, 
identify the principal findings and compare against recognised best practice. Key items 
included in the analysis were the proportions of studies using the different types of validation, 
investigation of sample sizes used and methods used for collecting and handling data. Where 
possible, an assessment was made of the effect of validation on reported model performance, 
and how this compared across alternative validation methodologies. 
The results are set out in Section 3. All charts were produced using Microsoft Excel.  
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3. Results 
The 100 papers selected for this project are listed in the Appendix. The flowchart in figure 1 
below outlines the selection process: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34 - flowchart of process for selecting 100 papers 
 
Orientation of analysis 
The analysis is set out in the following order. 
Firstly, section 3.1 covers the questions concerned with background information about the 
100 studies. Section 3.2 then covers aspects of the model building process, and sections 3.3 
and 3.4 deal with internal and external validation processes respectively. Finally, section 3.5 
3,190 papers found Literature search using 
Medline 
100 most recent papers 
downloaded 
Filtering criteria 
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94 papers retained, 6 
excluded  
Detailed review of 100 
papers 
100 papers included in 
study 
Further 6 papers 
downloaded 
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analyses model performance measures and, where possible, compares these between those 
reported as part of the model-building exercise and those reported as part of the validation 
process. 
3.1 Background information 
The 100 papers surveyed covered two entire years (2010 and 2011) and two partial years 
(2009 and 2012). The numbers of papers from each year were five from 2012, 38 from 2011, 
41 from 2010 and 16 from 2009. 
A key observation is that the vast majority of papers (95) concerned both the construction of a 
biomarker model along with the subsequent validation of that model. Only five papers purely 
concerned validation of a previously constructed model (refs S44, S53, S76, S85, S96).  
The full range of "omics" was covered, although transcriptomics was by far the largest 
category, being the sole subject of 78 of the papers. Genomics, proteomics, metabolomics and 
epigenomics were covered in 10, five, three and three papers respectively, whilst one paper 
(ref S47) considered the combination of both genomics and transcriptomics. 
60 of the papers concerned purely prognostic models (as defined in section 2), whilst 23 were 
purely predictive and 10 were purely diagnostic. Four covered both diagnostic and prognostic 
models, two covered both prognostic and predictive models and one (ref S30) covered all 
three types. Hence, 108 models were included in total. 
30 different cancer types were covered. The most common are shown in figure 2 below. 
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Figure 35 - types of cancer covered in the 100 papers 
 
The primary authors of the papers came from 21 different countries. The USA was by far the 
most frequent, at 34, followed by Japan and South Korea with nine, and China with seven. 
3.2 Model building 
3.2.1 Type of data used 
28 models were based on prospectively gathered data (as defined in section 2), 68 used 
retrospective data and for the remainder this determination was unclear. 12 of the prospective 
studies were planned, three were opportunistic and 13 could not be determined. 
The vast majority (92%) of the models used continuous variables, whilst the remainder used 
binary variables with two outcomes. 
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3.2.2 Definition of outcome being investigated 
Of the 15 diagnostic models covered, six were concerned with predicting whether an 
individual had cancer, and another three concerned existence of metastasis. The other six 
studies covered a variety of alternative outcomes. 
The majority of the 67 prognostic models concerned either overall survival (28) or disease-
free survival (29). Another six studies used metastasis-free survival as the primary outcome. 
Similarly, of the 26 predictive models, five were concerned with overall survival, seven with 
disease-free survival and three with metastasis-free survival. The primary outcome of a 
further nine was related in some way to the response to treatment (primarily chemotherapy). 
3.2.3 Biomarker selection process 
In the selection process for determining which biomarkers would be included in the model, 
only 15 studies used some form of adjustment to control false discovery rates on account of 
multiple testing. In 78 cases such an adjustment was clearly not made, whilst for the 
remainder the determination was unclear. 
12 studies used a completely separate data set to perform an initial filtering of biomarkers to 
be included in subsequent model building. The range of sample sizes used, where this could 
be determined (10 out of 12 cases), was 3 to 297 with an average of 92. On the other hand,  
seven studies (refs S12, S17, S25, S26, S35, S50 & S92) actually used the validation data at 
some point in the model-building process (thereby destroying the independence of the 
validation data). 
 
19 
 
In 14 cases the final number of biomarkers used in the model was unclear. One extreme 
model (ref S88), which used transcriptomic data to make prognoses about survival of glioma 
patients, was based on a principal components analysis of 5,000 biomarkers. The distribution 
of the numbers of biomarkers used is shown in figure 3 below. 
 
Figure 36 - distribution of numbers of biomarkers in final model 
 
3.2.4 Patient / sample data 
In 36 studies some patients / samples were removed from the full, starting data set as a result 
of missing information. This was also suspected for another three cases, although the evidence 
was unclear. 
The number of patients used for the model-building process ranged from 13 to 1,125, with an 
average of 131. Just over one half of the models were constructed using 100 patients or less.  
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The number of outcomes (e.g. death) amongst the patients ranged from 2 to 187, with an 
average of 41, in those cases which provided this information. However, in 38 cases the 
number of outcomes could not be determined. When it could be calculated, the average ratio 
of number of outcomes to number of biomarkers considered was only 2.8, and in only four 
cases (refs S15, S46, S58, S86) did this ratio exceed 10. 
3.2.5 Final model 
The formula / rule underlying the final, created model was explicitly stated (or sufficient 
information to deduce it was provided) in only 34 studies. A good example of this is reference 
S12, which set out the precise formula for a model to predict the risk of myeloma patients 
developing bone disease when treated with bisphophonates. 
92 studies used the model created to categorise patients into two risk groups (i.e. high and low 
risk). Seven models split patients into more than two groups (maximum six), whilst four 
models (refs S15, S32, S39, S47) used a continuous measurement with no splitting - for 
example, in reference S39 a model was created to predict the risk of an individual with oral 
premalignant lesion developing oral cancer . A variety of different methods was used to 
determine groups, and in 41 cases the methodology used was unclear. 
3.2.6 Type of validation 
The proportions of studies which used validation based on internal (i.e. same as model-
building) data sources or genuinely external data are set out in figure 4 below: 
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Figure 37 - breakdown of types of validation 
 
In total, 62 models were validated using external validation, whilst internal validation was 
used for 81 models. 
 
3.2.7 Summary of key points 
The majority of models were based on retrospectively gathered data. Most used continuous 
variables but dichotomised patients into two risk groups. In only one third of studies was it 
possible to deduce the actual final rule applied by the model. There was a large range in the 
number of patients used and in the number of biomarkers contained in the final model. The 
ratios of outcomes to numbers of biomarkers were small. Internal validation was used more 
often than external validation. 
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3.3 Internal validation 
Internal validation can be broken down into three different types: 
1. validation using different patient / sample data from the same source 
2. cross-validation with no separate data used 
3. permutation testing with no separate data used 
For those studies which used some form of internal validation, the breakdown between these 
three types is set out in figure 5 below. 
 
Figure 38 - distribution of different types of internal validation 
 
3.3.1 Cross-validation techniques 
The breakdown of the different ways in which cross-validation was utilised along with the 
purposes of the cross-validation are set out in figures 6 and 7 below. 
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Figure 39 - distribution of different types of cross-validation 
 
Figure 40 - distribution of different purposes of cross-validation 
LOOCV was by far the most popular technique used, followed by a variety of different  k-fold 
methods. Seven studies used a "nested" approach, whereby two separate cross-validation 
loops were used, one operating within the other.  
The key reason for using cross-validation was to estimate the performance of the model, 
although 19 studies used it for optimising the model-building process in some way (for 
example in reference S16 it was used to optimise the number of biomarkers to include in the 
model) and another three used it in the biomarker selection process. 
In 24 cases, the cross-validation procedure also included the biomarker selection process. 
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3.3.2 Permutation testing techniques 
18 studies used permutation testing as part of the model-building process. In 13 of these 
cases, the purpose of the permutation testing was to estimate the significance of the model's 
performance, whereas in the other five cases the purpose was to estimate the significance of 
the biomarker-selection process. 
The number of permutations used varied considerably between studies, as set out in figure 8 
below. 
 
Figure 41 - distribution of numbers of permutations used 
 
3.3.3 Internal validation with separate data 
38 studies used an internal validation procedure which was based on separate data from the 
same source as the data used for model building. This meant that the original data set was 
split into two, one portion used for model building and the other for model testing. The 
distribution of the different ways in which this was achieved are set out in figure 9 below. 
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Figure 42 - distribution of methods used for splitting data for internal validation 
 
The most popular method was a single, random split of data, which was used in one half of 
cases. In 11 cases the approach taken could not be determined. 
The number of patients used for validation ranged from 13 to 337, with an average of 76. The 
number of outcomes amongst these patients ranged from 5 to 96, with an average of 28, in 
those cases which provided this information. However, in 17 cases the number of outcomes 
could not be determined. 
3.3.4 Comparison of performance results between internal validation methods 
Only a small number of studies used more than one method of internal validation. Hence it is 
difficult to compare how each performed in the same study. An alternative is to look across 
studies - for example, using classification accuracy as the measure of performance, the 
average accuracy rate for models which used cross-validation was 87.6%. This compares with 
an average rate of 78.9% for models which used internal validation with a separate data set. 
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3.3.5 Summary of key points 
Around 75% of studies used some form of internal validation. The most common type of 
internal validation used was cross-validation, followed by the use of a split data set. For the 
latter, there was a large range in the number of patients used. Looking across studies, cross-
validation tended to result in higher reported model accuracy than internal validation with 
separate data. 
 
3.4 External validation 
62 of the models considered were validated using external datasets. Of these, nine validation 
procedures were based on prospectively gathered data, whereas 50 were based on 
retrospective analysis of previously gathered data. The determination for the remaining cases 
was unclear.  Of the nine prospective cases, five appeared to be planned, two opportunistic 
and for two the determination was unclear. 
42 studies which used external validation were based on patient data gathered from different 
locations and by someone other than the research team who created the model. 44 cases used 
just one external data set, whilst 10 used two and eight used three or more. 
In 17 cases, some patients were removed from the starting external dataset as a result of 
missing information. The number of patients used ranged from 10 to 1,083, with an average 
of 194. The number of outcomes amongst these patients ranged from 4 to 112, with an 
average of 45, in those cases which provided this information. However, in 37 cases the 
number of outcomes could not be determined. 
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Summary of key points 
Around 60% of studies employed validation using external data. There was a wide range in 
the numbers of patients used and the numbers of outcomes amongst those patients. 
 
3.5 Comparison of validation and model-building performance measures 
The following paragraphs compare the performance of the models when applied to the 
original data set used for model-building and the validation data sets. 
3.5.1 Area under the curve (AUC) 
One of the most popular methods for analysing the discriminative ability of a model is the so-
called area-under-the-curve (AUC) applied to the receiver operating characteristics (ROC) 
curve. The ROC curve plots 1-specificity on the x-axis versus sensitivity on the y-axis for all 
possible model cut-off points. The AUC then gives a measure of how well the model can 
discriminate cases, with a value of 1 indicating perfect discrimination and a value of 0.5 
indicating performance no better than random. 
The AUC was reported for 17 of the models created. For six, a corresponding AUC value was 
reported based on a separate, internal data set, and for seven this was performed on an 
external data set. Details of the reported AUC measurements are set out in table 6 below. 
Ref Training data Internal validation data External validation data 
 Sample 
size 
AUC 
value 
Sample 
size 
AUC 
value 
Change 
Sample 
size 
AUC 
value 
Change 
S2 61 0.95 - - - 24 0.88 -0.07 
S29 113 0.87 - - - - - - 
S32 96 0.87 78 0.80 -0.07 - - - 
S98 127 0.84 - - - 130 0.74 -0.10 
S2 50 0.99 - - - - - - 
S20 122 0.71 172 0.61 -0.10 - - - 
S35 118 0.75 - - - - - - 
S49 242 0.76 - - - - - - 
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S59 128 0.77 104 0.74 -0.03 94 & 33 
0.61 & 
0.68 
-0.16 &    
-0.09 
S60 247 0.83 - - - 91 0.72 -0.11 
S62 153 0.81 - - - - - - 
S74 110 0.96 - - - 87 0.67 -0.29 
S7 36 0.87 24 0.82 -0.05 - - - 
S12 172 0.81 56 0.95 +0.14 - - - 
S47 30 0.84 69 0.61 -0.23 - - - 
S87 47 0.89 - - - 20 0.77 -0.12 
S99 252 0.78 - - - 224 0.73 -0.05 
         
Average change relative to 
training result 
 
 -0.06 
  
-0.12 
Table 6 - comparison of AUC values between training and validation datasets 
Although the number of cases for which the AUC was reported is small, there is a clear trend 
showing that the validation AUC is usually lower than that obtained using the training data. 
For internal validation exercises, the difference between the AUCs reported for validation and 
training data ranged from -0.23 to +0.14, with an average of -0.06. When external validation 
was used, the average difference was twice as large at -0.12, with a range of -0.29 to -0.05. 
3.5.2 Sensitivity and specificity 
In 29 cases the sensitivity and/or specificity of the model applied to the training data was 
reported. For six of these cases sensitivity and specificity were also reported in a separate 
internal data set, and for nine both measures were also reported in a separate external data set. 
Details are set out  in table 7 below. Figures in brackets are the change relative to the training 
data set result. 
Ref Sample sizes Sensitivity values Specificity values 
Training Internal External Training Internal External Training Internal External 
S2 50 - - 0.91 - - 0.75 - - 
S4 20 - - 0.80 - - 0.76 - - 
S41 21 - - 1.00 - - 1.00 - - 
S49 242 - - - - - 0.60 - - 
S58 229 - - 0.73 - - 0.66 - - 
S59 128 - - 0.63 - - 0.81 - - 
S64 160 - - 0.88 - - 0.86 - - 
S66 50 34 85 0.77 0.22 0.33 0.86 1.00 0.94 
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(-0.55) (-0.44) (+0.14) (+0.08) 
S67 103 - - 0.82 - - 0.91 - - 
S74 110 - 87 0.89 - 
0.64 
(-0.25) 
0.86 - 
0.69 
(-0.17) 
S79 103 - - 0.91 - - 0.94 - - 
S84 56 - - 0.78 - - 0.79 - - 
S91 61 - 267 0.64 - 
0.62 
(-0.02) 
0.67 - 
0.67 
 (0) 
S95 27 - - 0.92 - - 0.93 - - 
S2 61 - 24 0.64 - 
1.00 
(+0.36) 
0.94 - 
0.67 
(-0.27) 
S4 141 - 151 1.00 - 1.00 (0) 1.00 - 
0.96 
(-0.04) 
S30 213 - 42 0.85 - 
0.89 
(+0.04) 
0.81 - 
0.54 
(-0.27) 
S19 44 44 - 0.75 
0.91 
(+0.16) 
- 1.00 
0.91 
(-0.09) 
- 
S40 157 80 - 0.94 
0.98 
(+0.04) 
- 0.96 
1.00 
(+0.04) 
- 
S41 71 68 - 1.00 
1.00  
(0) 
- 1.00 
1.00  
(0) 
- 
S12 172 - - 0.87 - - 0.72 - - 
S13 31 - - 0.79 - - 0.83 - - 
S18 50 34 - 1.00 
0.88 
(-0.12) 
- 0.59 
0.54 
(-0.05) 
- 
S22 57 37 - 0.87 
0.73 
(-0.14) 
- 0.82 
0.86 
(+0.04) 
- 
S43 27 - - 0.77 - - 0.93 - - 
S45 28 - 14 0.96 - 
0.72 
(-0.24) 
0.80 - 
1.00 
(+0.20) 
S56 25 - 10 0.68 - 
0.75 
(+0.07) 
0.93 - 
0.83 
(-0.10) 
S92 27 - - 0.75 - - 0.67 - - 
S99 252 - 224 0.82 - 
0.84 
(+0.02) 
0.63 - 
0.52 
 (-0.11) 
Average change relative to training result -0.10 -0.05  +0.01 -0.08 
Table 7 - comparison of sensitivity and specificity values between training and validation data sets 
The differences between validation and training results are variable (maximum difference of 
+0.36, lowest of -0.55), in part because some of the sample numbers involved are very small. 
However, generally speaking there is a trend for the validation results to be less favourable 
than the training results. 
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Another way of considering these statistics is to calculate Youden's Index, which equals the 
sum of sensitivity and specificity minus 1. The index ranges from -1 to 1, with 1 implying 
perfect predictive ability, 0 implying no predictive ability and -1 implying totally incorrect 
predictive ability. 
For the six cases in table 7 which used internal validation, Youden's Index value reduced on 
average by 0.09 between the training and validation data sets (and in fact it actually increased 
in two cases). For the nine external validation cases, the average reduction was greater at 0.13, 
and only one case resulted in an increase. 
3.5.3 Calibration 
Only one paper (ref S58)  included any information on model calibration, and even then it was 
only shown for the combined training and validation data sets with no split between them. 
3.5.4 Decision analysis 
None of the 100 papers included any information on cost / benefit analysis of applying the 
model in practice. 
3.5.5 Summary of key points 
Relevant performance measures were presented in only a small proportion of studies. When 
they were presented, results using validation data tended to be worse than those based on the 
data used to create the model. 
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4. Discussion 
The analysis of the 100 papers has highlighted a number of issues concerning the way in 
which validation studies are undertaken. 
Firstly, only 5% of the papers were purely concerned with the validation of a previously 
constructed model, with the vast majority covering both the construction and subsequent 
validation of a model by the same research team. This phenomenon has previously been 
observed
6
. Whilst it is understandable that individuals may prefer to concentrate on creating 
their own models rather than validating someone else's work, it is worrying that little effort 
seems to be being put into genuine, external validation of models created by other researchers. 
It is encouraging that over 50% of studies used external validation. However, it is of concern 
that internal validation is more common than external validation given that the former is 
considered to be prone to overstating a model's predictive ability
5
. Again this trend for more 
frequent internal validation has been observed in previous research
6
, and is understandable 
when suitable data cannot be found in adequate quantity. The tendency for internal validation 
to produce more favourable measures of performance than external validation was again 
observed in the small number of cases for which a direct comparison could be made. 
There are a couple of particular concerns in connection with internal validation practices. 
Firstly, cross-validation was the most popular method of internal validation. In order to 
minimise the risk of bias in performance measurement, it is important that cross-validation 
covers the entire model-building process, including the selection of biomarkers
7
. However, 
this part of the process was covered in less than half of the cross-validation exercises 
encountered in the review.  
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Secondly, for those cases where internal validation involved the split of the data set into 
training and test sets, there was a wide range of sample sizes used. The average number of 
patients was 76, and the average number of outcomes was only 28. The typical ratio of 
outcomes to biomarkers in the model was much lower than the figure of 10 which is 
considered to be a reasonable minimum for acceptable statistical power
6
. Only three studies 
met this criterion. These small sample sizes bring into question the ability of the validation 
exercises to adequately assess model performance. Previous research
8
 has indicated that, in 
certain circumstances, the rule of thumb may be relaxed below 10 outcomes per biomarker, 
but even then the analysis in this study suggests that in many cases the number of outcomes is 
still inadequate. 
Another concern is that in 45% of internal validation cases the number of outcomes amongst 
the patient population used could not be determined. This too is a phenomenon which has 
been observed before
9
, and means that the standard of reporting often does not meet the 
REMARK guidelines
10
, which were established to encourage transparent reporting in 
prognostic studies involving tumour biomarkers. 
The issue of inadequate sample sizes and unclear reporting of numbers of outcomes was also 
a concern for those studies which used external validation. Previous research has suggested 
that for effective external validation, the validation data should include at least 100 outcomes 
and another 100 non-outcomes
11
. The analysis in this project has shown that the numbers 
used, in particular for outcomes (where this could be determined), were generally a lot lower 
than this benchmark, with only two studies meeting it. 
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This study has also identified that in over 25% of external validation exercises, some patients 
were removed from the initial validation data set because of incomplete data. The issue here is 
that it is unlikely that missing data is a random event, but rather that it is linked in some way 
to characteristics of the disease in question, and therefore possibly to the chance of an 
outcome occurring. This means that excluding patients because of missing data may lead to 
bias in the performance measurement
12
. 
Linked to the above issue is the fact that over 80% of external validation exercises used 
retrospectively gathered data. Retrospective studies have the potential to introduce bias into 
the results because of the availability of tumour material
13
. Again, the overuse of retrospective 
studies is a phenomenon which has previously been observed in the context of reporting of 
methods used in developing prognostic models
14
. Another observation is that the same 
retrospective data has often been used in the creation and/or validation of several different 
models - for example, the same data set was used in five separate studies involving lung 
cancer. Whilst one can understand this from the practical point of view of obtaining suitable 
data, the use of the same data set for different studies reduces the independence of these 
studies.  
Another observation relating to data is that in 7% of studies the validation data was actually 
used in some part of the model-building process. This is an unfortunate practice as it violates 
the independence of the validation data from the model, and can therefore lead to 
"information leak" which can compromise the accuracy of the validation results
1,7
. 
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Turning to the reporting of performance measurements, the use of standard statistical 
techniques (such as AUC) for reporting discrimination was uncommon. Much greater 
emphasis was placed on reporting Kaplan-Meier estimates of survival, with associated p-
values, and also on hazard ratios from analyses using Cox proportional hazards. This in turn 
followed on from the very common approach of dichotomising patients into two risk-groups, 
rather than treating model output as a continuous variable (which in most cases it was). This 
is generally viewed as a bad idea
15
, as it introduces an artificial, arbitrary cut-off point which 
has no biological justification and can lead to biased performance measurements. 
Calibration was only reported in one study. Perhaps unsurprisingly, none of the studies 
included any detailed analysis of how the model could impact actual clinical decision making. 
Given that only a very small proportion of biomarker models are eventually adopted into 
clinical practice
2
, a review of the way in which such models are created and validated would 
seem necessary.  
Probably the most important issue is that of scale - i.e. using very large sample sizes, for both 
model creation and subsequent external validation. This will require more collaboration and 
sharing of data between research teams (ideally on a worldwide basis), rather than the present 
system of individual research teams working on their own models with limited access to data 
(a lot of which is retrospectively gathered). Such collaboration may be difficult to coordinate 
and expensive, but then there currently seems to be a lot of time and effort wasted on 
producing models which will never get anywhere near being used in practice. 
As well as greater collaboration, more emphasis needs to be placed on proper validation. This 
could be achieved, for example, through the peer-review process when papers are submitted 
for publication. 
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In conclusion, even this relatively small study has identified several areas of concern with the 
way in which validation studies have been conducted in recent years. Many of these issues, in 
particular those relating to inadequate sample sizes and lack of transparency in reporting data, 
were also present in the model-building process as well as validation. 
As well as the small size, another key limitation of this study is that all the work was 
performed by one individual. Ideally at least two people would have reviewed all the papers 
and then compared their analyses, thereby providing a check on the results. In many of the 
papers reviewed there was a lack of clarity in reporting, which meant that judgements had to 
be made as to how to answer certain questions. It would have been preferable for these 
judgements to be performed by more than one person, to reduce the possibility of personal 
bias entering the analysis. 
 
  
36 
 
Appendix - 100 papers included in survey 
 
S1 
 
Yu K-D, Huang A-J, Fan L, Li W-F and Shao Z-M (2012) Genetic variants in 
oxidative stress-related genes predict chemoresistance in primary breast cancer: a 
prospective observational study and validation. Cancer Research 72(2), 408-419 
 
S2 Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJLH, Moller S et al (2012) 
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome 
in prostate cancer. Oncogene 31, 978-991 
 
S3 Patel JP, Gonen M, Figueroa ME, Fernandez M, Sun Z et al (2012) Prognostic 
relevance of integrated genetic profiling in acute myeloid leukemia. The New 
England Journal of Medicine 366(12), 1079-1089 
 
S4 Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS et al (2012) Metabolomic 
NMR fingerprinting to identify and predict survival of patients with metastatic 
colorectal cancer. Cancer Research 72(1), 356-364 
 
S5 Stretch C, Eastman T, Mandal R, Eisner R, Wishart DS et al (2012) Prediction of 
skeletal muscle and fat mass in patients with advanced cancer using a metabolomic 
approach. The Journal of Nutrition 142, 14-21 
 
S6 Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM et al (2011) Robust gene 
expression signature from formalin-fixed paraffin-embedded samples predicts 
prognosis of non-small-cell lung cancer patients. Clinical Cancer Research 17(17), 
5705-5714 
 
S7 Kerr DA and Wittliff JL (2011) A five-gene model predicts clinical outcome in 
ER+/PR+ early-stage breast cancers treated with adjuvant tamoxifen. Hormones and 
Cancer 2, 261-271 
 
S8 Hu J, Wang Z, Fan J, Dai Z, He Y-F et al (2011) Genetic variations in plasma 
circulating DNA of HBV-related hepatocellular carcinoma patients predict 
recurrence after liver transplantation. PLoS One 6(10), e26003 
 
S9 Chen D-T, Hsu Y-L, Fulp WJ, Coppola D, Haura EB et al (2011) Prognostic and 
predictive value of a malignancy-risk gene signature in early-stage non-small cell 
lung cancer. Journal of National Cancer Institute 103, 1859-1870 
 
S10 Reis PP, Waldron L, Perez-Ordonez B, Pintilie M, Galloni NN et all (2011) A gene 
signature in histologically normal surgical margins is predictive of oral carcinoma 
recurrence. BMC Cancer 11:437 
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S11 Hao K, Lamb J, Zhang C, Xie T, Wang K et al (2011) Clinicopathologic and gene 
expression parameters predict liver cancer prognosis. BMC Cancer 11:481 
 
S12 Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J et al (2011) A gene 
expression-based predictor for myeloma patients at high risk of developing bone 
disease on bisphosphonate treatment. Clinical Cancer Research 17(19), 6347-6355 
 
S13 Maher SG, McDowell DT, Collins BC, Muldoon C, Gallagher WM et al (2011) 
Serum proteomic profiling reveals that pretreatment complement protein levels are 
predictive of esophageal cancer patient response to neoadjuvant chemoradiation. 
Annals of Surgery 254, 809-817 
 
S14 Miller LD, Coffman LG, Chou JW, Black MA, Bergh J et al (2011) An iron 
regulatory gene signature predicts outcome in breast cancer. Cancer Research 
71(21), 6728-6737 
 
S15 Cuzick J, Dowsett M, Pineda S, Wale C, Salter J et al (2011) Prognostic value of a 
combined estrogen receptor, progetserone receptor, Ki-67, and human epidermal 
growth factor receptor 2 immunohistochemical score and comparison with the 
genomic heath recurrence score in early breast cancer. Journal of Clinical Oncology 
29, 4273-4278 
 
S16 Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C et al (2011) Development 
of a hypoxia gene expression classifier with predictive impact for hypoxic 
modification of  radiotherapy in head and neck cancer. Cancer Research 71(17), 
5923-5931 
 
S17 Rinaldi A, Mian M, Kwee I, Rossi D, Deambrogi C et al (2011) Genome-wide DNA 
profiling better defines the prognosis of chronic lymphocytic leukaemia. British 
Journal of Haematology 154, 590-599 
 
S18 Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N et al (2011) Prediction of 
pathologic complete response to sequential paclitaxel and 5-
fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for 
breast cancers. Cancer 117, 3682-3690 
 
S19 Huang L, Zheng M, Zhou Q-M, Zhang M-Y, Jia W-H et al (2011) Identification of a 
gene-expression signature for predicting lymph node metastasis in patients with early 
stage cervical carcinoma. Cancer 117, 3363-3373 
 
S20 Gao Q, Wang X-Y, Qiu S-J, Zhou J, Shi Y-H et al (2011) Tumor stroma reaction-
related gene signature predicts clinical outcome in human hepatocellular carcinom. 
Cancer Science 102, 1522-1531 
 
S21 Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J et al (2011) A seven-gene 
prognostic model for platinum-treated ovarian carcinomas. British Journal of Cancer 
105, 304-311 
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S22 Cassado E, Garcia VM, Sanchez JV, Blanco M, Maurel J et al (2011) A combined 
strategy of SAGE and quantitative PCR provides a 13-gene signature that predicts 
preoperative chemoradiotherapy response and outcome in renal cancer. Clinical 
Cancer Research 17(12), 4145-4154 
 
S23 Kim W-J, Kim S-J, Jeong P, Yun S-K, Cho I-C (2011) A four-gene signature 
predicts disease progression in muscle invasive bladder cancer. Molecular Medicine 
17(5-6), 478-485 
 
S24 Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L et al (2011) A genomic 
predictor of response and survival following taxane-anthracycline chemotherapy for 
invasive breast cancer. JAMA 305(18), 1873-1881 
 
S25 Bertucci F, Borie N, Roche H, Bachelot T, le Doussal J-M et al (2011) Gene 
expression profile predicts outcome after anthracycline-based adjuvant 
chemotherapy in early breast cancer. Breast Cancer Research and Treatment 127, 
363-373 
 
S26 Mitra R, Lee J, Jo J, Milani M, McClintick JN et al (2011) Prediction of post-
operative recurrence-free survival in non-small cell lung cancer by using an 
internationally validated gene expression model. Clinical Cancer Research 17(9), 
2934-2946 
 
S27 Navab R, Strumpf D, Bandarchi B, Zhu C-Q, Pintilie M et al (2011) Prognostic 
gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung 
cancer. PNAS 108(17), 7160-7165 
 
S28 Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J et al (2011) 
Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumural 
CD8+ lymphocyte invasion as an independent predictor of survival. Journal of 
Clinical Oncology 29, 1539-1546 
 
S29 Mendez E, Lohavanichbutr P, Fan W, Houck JR, Rue TC et al (2011) Can a 
metastatic gene expression profile outperform tumor size as a predictor of occult 
lymph node metastasis in oral cancer patients? Clinical Cancer Research 17(8), 
2466-2473 
 
S30 Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G et al (2011) Distinct p53 
gene signatures are needed to predict prognosis and response to chemotherapy in 
ER-positive and ER-negative breast cancers. Clinical Cancer Research 17(8), 2591-
2601 
 
S31 Zhang Y-Z, Zhang L-H, Gao Y, Li C-H, Jia S-Q et al (2011) Discovery and 
validation of prognostic markers in gastric cancer by genome-wide expression 
profiling. World Journal of Gastroenterology 17(13), 1710-1717 
 
S32 Tamayo P, Cho Y-J, Tsherniak A, Greulich H, Ambrogio L et al (2011) Predicting 
relapse in patients with medulloblastoma by integrating evidence from clinical and 
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genomic features. Journal of Clinical Oncology 29, 1415-1423 
 
S33 Cho JY, Lim JY, Cheong JH, Park Y-Y, Yoon S-L et al (2011) Gene expression 
signature-based prognostic risk score in gastric cancer. Clinical Cancer Research 
17(7), 1850-1857 
 
S34 Gobble RM, Qin L-X, Brill ER, Angeles CV, Ugras S et al (2011) Expression 
profiling of liposarcoma yields a multigene predictor of patient outcome and 
identifies genes that contribute to liposarcomagenesis. Cancer Research 71(7), 2697-
2705 
 
S35 Zhao X, Rodland EA, Sorlie T, Naume B, Langerod A et al (2011) Combining gene 
signatures improves prediction of breast cancer survival. PLoS One 6(3): e17845 
 
S36 Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J et al (2011) Genomic and 
epigenomic integration identifies a prognostic signature in colon cancer. Clinical 
Cancer Research 17(6), 1535-1545 
 
S37 Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B et al (2011) A gene 
expression signature identifies two prognostic subgroups of basal breast cancer. 
Breast Cancer Research and Treatment 126, 407-420 
 
S38 Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F et al (2011) The host genetic 
background of DNA repair mechanisms is an independent predictor of survival in 
diffuse large B-cell lymphoma. Blood 117(8), 2405-2413 
 
S39 Saintigny P, Zhang L, Fan Y-H, El-Naggar AK, Papadimitrakopoulou VA et al 
(2011) Gene expression profiling predicts the development of oral cancer. Cancer 
Prevention Research 4(2), 218-229 
 
S40 Balgobind BV, Van den Heuvel-Elbrink MM, De Menezes RX, Reinhardt D, 
Hollink IHIM et al (2011) Evaluation of gene expression signatures predictive of 
cytogenetic and molecular subtypes of pedriatic acute myeloid leukemia. 
Haematologica 96(2), 221-230 
 
S41 Gotoh M, Arai E, Wakai-Ushijima S, Hiraoka N, Kosuge T et al (2011) Diagnosis 
and prognostication of ductal adenocarcinomas of the pancreas based on genome-
wide DNA methylation profiling by bacterial artificial chromosome array-based 
methylated CpG island amplification. Journal of Biomedicine and Biotechnology 
2011, 780836 
 
S42 Salazar R, Roepman P, Capella G, Moreno V, Simon I et al (2010) Gene expression 
signature to improve prognosis prediction of stage II and III colorectal cancer. 
Journal of Clinical Oncology 29, 17-24 
 
S43 Li Y, Dang TA, Shen J, Hicks J, Chintagumpala M et al (2011) Plasma proteome 
predicts chemotherapy response in osteosarcoma patients. Oncology Reports 25, 
303-314 
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S44 Onozato W, Yamashita K, Yamahshita K, Kuba T, Katoh H et al (2011) Genetic 
alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 
years of age. Journal of Surgical Oncology 103, 25-33 
 
S45 Barros Filho MC, Katayama MLH, Brentani H, Abreu APS, Barbosa EM et al 
(2010) Gene trio signatures as molecular markers to predict response to doxorubicin 
cyclophosphamide neoadjuvant chemotherapy in breast cancer patients. Brazilian 
Journal of Medical and Biological Research 43, 1225-1231 
 
S46 Tong D, Heinze G, Pils D, Wolf A, Singer CF et al (2010) Gene expression of 
PMP22 is an independent prognostic factor for disease-free and overall survival in 
breast cancer patients. BMC Cancer 10:682 
 
S47 Paik H, Lee E and Lee D (2010) Relationships between genetic polymorphisms and 
transcriptional profiles for outcome prediction in anticancer agent treatment. BMB 
Reports 43(12), 836-841 
 
S48 Daghistani M, Marin D, Khorashad JS, Wang L, May PC et al (2010) EVI-1 
oncogene expression predicts survival in chronic-phase CML patients resistant to 
imatinib treated with second-generation tyrosine kinase inhibitors. Blood 116(26), 
6014-6017 
 
S49 Roessler S, Jia H-L, Budhu A, Forgues M, Ye Q-H et al (2010) A unique metastasis 
gene signature enables prediction of tumor relapse in early-stage hepatocellular 
carcinoma patients. Cancer Research 70(24), 10202-10212 
 
S50 Kim SM, Park Y-Y, Park ES, Cho JY, Izzo JG et al (2010) Prognostic biomarkers 
for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS 
One 5(11): e15074 
 
S51 Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R et al (2010) Inflammatory 
and MicroRNA gene expression as prognostic classifier of Barrett's-Associated 
esophageal adenocarcinoma. Clinical Cancer Research 16(23), 5824-5834 
 
S52 Peters CJ, Rees JRE, Hardwick RH, Hardwick JS, Vowler SL et al (2010) A 4-gene 
signature predicts survival of patients with resected adenocarcinoma of the 
esophagus, junction, and gastric cardia. Gastroenterology 139, 1995-2004 
 
S53 Kawarazaki S, Taniguchi K, Shirahata M, Kukita Y, Kanemoto M et al (2010) 
Conversion of a molecular classifier obtained by gene expression profiling into a 
classifier based on real-time PCR: a prognosis predictor for gliomas. BMC Medical 
Genomics 3:52 
 
S54 Zhu C-Q, Strumpf D, Li C-Y, Li Q, Liu N et al (2010) Prognostic gene expression 
signature for squamous cell carcinoma of lung. Clinical Cancer Research 16(20), 
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5038-5047 
 
 
S55 Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK et al (2010) Global 
levels of specific histone modifications and an epigenetic gene signature predict 
prostate cancer progression and development. Cancer Epidemiology, Biomarkers and 
Prevention 19(10), 2611-2622 
 
S56 Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A et al (2010) Prediction 
of the response to chemotherapy in advanced esophageal cancer by gene expression 
profiling of biopsy samples. International Journal of Oncology 37, 1113-1120 
 
S57 Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S et al (2010) A gene expression 
signature that predicts the therapeutic response of the basal-like breast cancer to 
neoadjuvant chemotherapy. Breast Cancer Research and Treatment 123, 691-699 
 
S58 Wan Y-W, Sabbagh E, Raese R, Qian Y, Luo D et al (2010) Hybrid models 
identified a 12-gene signature for lung cancer prognosis and chemoresponse 
prediction. PLoS One 5(8):e12222 
 
S59 Kim J, Hong SJ, Park JY, Park JH, Yu Y-S et al (2010) Epithelial-mesenchymal 
transition gene signature to predict clinical outcome of hepatocellular carcinoma. 
Cancer Science 101(6), 1521-1528 
 
S60 Van Malenstein H, Gevaert O, Libbrecht L, Daemen A, Allemeersch J et al (2010) A 
seven-gene set associated with chronic hypoxia of prognostic importance in 
hepatocellular carcinoma. Clinical Cancer Research 16(16), 4278-4288 
 
S61 Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA et al (2010) A six-gene 
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